[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 73 of about 73
1. Schoene-Bake JC, Parpaley Y, Weber B, Panksepp J, Hurwitz TA, Coenen VA: Tractographic analysis of historical lesion surgery for depression. Neuropsychopharmacology; 2010 Dec;35(13):2553-63
MedlinePlus Health Information. consumer health - Depression.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Various surgical brain ablation procedures for the treatment of refractory depression were developed in the twentieth century.
  • It is possible that the observed clinical improvements of these various surgical procedures may reflect shared influences on presently unspecified brain affect-regulating networks.
  • Such possibilities can now be analyzed using modern brain connectivity procedures such as diffusion tensor imaging (DTI) tractography.
  • Accordingly, modestly sized historical lesions, especially of the anatomical overlap areas, were 'implanted' in brain-MRI scans of 53 healthy subjects.
  • [MeSH-major] Brain / anatomy & histology. Depression / surgery. Neural Pathways / anatomy & histology. Neuroanatomical Tract-Tracing Techniques / methods. Psychosurgery / methods

  • Genetic Alliance. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Image Anal. 2001 Jun;5(2):143-56 [11516708.001]
  • [Cites] Neurosurg Focus. 2008;25(1):E2 [18590379.001]
  • [Cites] Neurosurgery. 2002 May;50(5):1043-9; discussion 1049-52 [11950407.001]
  • [Cites] Neurol Med Chir (Tokyo). 2002 Sep;42(9):365-71 [12371591.001]
  • [Cites] JAMA. 2003 Jun 18;289(23):3095-105 [12813115.001]
  • [Cites] Nat Neurosci. 2003 Jul;6(7):750-7 [12808459.001]
  • [Cites] Neurosurg Clin N Am. 2003 Apr;14(2):199-212 [12856488.001]
  • [Cites] Neurosurg Clin N Am. 2003 Apr;14(2):225-35 [12856490.001]
  • [Cites] Stereotact Funct Neurosurg. 2002;79(3-4):234-44 [12890982.001]
  • [Cites] Br J Psychiatry. 1969 Mar;115(520):257-66 [4893673.001]
  • [Cites] Exp Neurol. 1973 Sep;40(3):798-805 [4124980.001]
  • [Cites] Br J Psychiatry. 1973 Aug;123(573):141-8 [4582235.001]
  • [Cites] Med J Aust. 1973 Aug 25;2(8):366-71 [4749527.001]
  • [Cites] Postgrad Med J. 1973 Dec;49(578):860-4 [4618905.001]
  • [Cites] Br J Psychiatry. 1976 Mar;128:226-40 [1252686.001]
  • [Cites] Stereotact Funct Neurosurg. 1991;57(4):175-94 [1842976.001]
  • [Cites] J Clin Psychiatry. 1993 Nov;54(11):405-18 [8270583.001]
  • [Cites] Br J Psychiatry. 1994 Nov;165(5):599-611; discussion 612-3 [7866675.001]
  • [Cites] Annu Rev Psychol. 1995;46:209-35 [7872730.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1995 Winter;7(1):103-12 [7711480.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1995 Spring;7(2):230-4 [7626968.001]
  • [Cites] Arch Gen Psychiatry. 1961 Jun;4:561-71 [13688369.001]
  • [Cites] Cereb Cortex. 2005 Jan;15(1):31-9 [15238447.001]
  • [Cites] Neuron. 2005 Mar 3;45(5):651-60 [15748841.001]
  • [Cites] Gesnerus. 2005;62(1-2):77-101 [16201322.001]
  • [Cites] Neuroimage. 2006 May 15;31(1):440-57 [16466680.001]
  • [Cites] Stereotact Funct Neurosurg. 2006;84(5-6):228-35 [17063044.001]
  • [Cites] Neuroimage. 2007 Jan 1;34(1):144-55 [17070705.001]
  • [Cites] Brain. 2007 Mar;130(Pt 3):630-53 [17293361.001]
  • [Cites] Neuroimage. 2007 May 1;35(4):1531-7 [17391987.001]
  • [Cites] Ann N Y Acad Sci. 2007 May;1104:70-88 [17344522.001]
  • [Cites] Brain Res Rev. 2007 Dec;56(2):283-321 [17905440.001]
  • [Cites] Neuropsychopharmacology. 2008 Jan;33(2):368-77 [17429407.001]
  • [Cites] J Clin Neurosci. 2008 Feb;15(2):138-42 [18068369.001]
  • [Cites] CNS Spectr. 2008 Aug;13(8):663-81 [18704022.001]
  • [Cites] Biol Psychiatry. 2008 Sep 15;64(6):461-7 [18639234.001]
  • [Cites] Psychiatry Res. 2008 Nov 30;164(2):132-42 [18945599.001]
  • [Cites] Nat Neurosci. 2009 Jan;12(1):32-4 [19029888.001]
  • [Cites] Biol Psychiatry. 2009 Feb 15;65(4):276-82 [19013554.001]
  • [Cites] J Clin Invest. 2009 Apr;119(4):717-25 [19339763.001]
  • [Cites] Science. 2009 Apr 17;324(5925):354-9 [19299587.001]
  • [Cites] Neurosurgery. 2009 Jun;64(6):1106-14; discussion 1114-5 [19487890.001]
  • [Cites] J Neurosurg. 2009 Dec;111(6):1209-15 [19480538.001]
  • [Cites] Biol Psychiatry. 2010 Jan 15;67(2):117-24 [19819426.001]
  • [Cites] Neuropsychopharmacology. 2010 Jan;35(1):4-26 [19812543.001]
  • [Cites] CNS Drugs. 2010 Feb;24(2):131-61 [20088620.001]
  • [Cites] Neuron. 2010 Mar 25;65(6):748-51 [20346752.001]
  • [Cites] J Psychiatr Res. 2010 Aug;44(11):683-7 [20096858.001]
  • [Cites] Neuroimage. 2008 Apr 1;40(2):570-82 [18255316.001]
  • [Cites] Biol Psychiatry. 2008 Apr 1;63(7):670-7 [17916331.001]
  • [Cites] Cereb Cortex. 2008 Jun;18(6):1374-83 [17928332.001]
  • [Cites] J Nerv Ment Dis. 2008 May;196(5):405-10 [18477883.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Aug 29;356(1412):1293-322 [11545704.001]
  • (PMID = 20736994.001).
  • [ISSN] 1740-634X
  • [Journal-full-title] Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
  • [ISO-abbreviation] Neuropsychopharmacology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3055575
  •  go-up   go-down


2. McCarthy BJ, Kruchko C, Central Brain Tumor Registry of the United States: Consensus conference on cancer registration of brain and central nervous system tumors. Neuro Oncol; 2005 Apr;7(2):196-201
Genetic Alliance. consumer health - Brain Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consensus conference on cancer registration of brain and central nervous system tumors.
  • The passage of Public Law 107-260, the Benign Brain Tumor Cancer Registries Amendment Act, in October 2002 has made the collection of all primary brain tumors a reality.
  • However, at the first Consensus Conference on Brain Tumor Definition for Registration in 2002, and during the development of training materials for benign brain tumor collection, several issues were identified that were tabled for future discussion.
  • These and other issues were addressed at the subsequent 2003 Consensus Conference on Cancer Registration of Brain and Central Nervous System Tumors, at which the Central Brain Tumor Registry of the United States facilitated a discussion among epidemiologists, neurosurgeons, and neuropathologists.
  • (1) amend the histology coding scheme for cysts and tumor-like lesions that currently have a code in the third edition of the International Classification of Disease for Oncology (ICDO), (2) collect data on all instances of specific cysts and tumor-like lesions that are located in brain and other CNS sites but currently lack ICDO codes, (3) establish a new ICDO topography site for skull base tumors for the brain and CNS, and (4) collect data on genetic syndromes in patients diagnosed with brain or CNS tumors.
  • Because classification of primary intracranial and other CNS tumors is dynamic, and the registration and coding of these tumors will need to be periodically reviewed.
  • [MeSH-major] Central Nervous System Neoplasms / classification. Central Nervous System Neoplasms / pathology. Registries

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1998 Jul 15;90(14):1039-71 [9672254.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):134-45 [11916506.001]
  • (PMID = 15831238.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  • [Other-IDs] NLM/ PMC1871892
  •  go-up   go-down


3. Liu J, Zheng S, Yu JK, Zhang JM, Chen Z: Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor. J Zhejiang Univ Sci B; 2005 Jan;6(1):4-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor.
  • To screen and evaluate protein biomarkers for the detection of gliomas (Astrocytoma grade I-IV) from healthy individuals and gliomas from brain benign tumors by using surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) coupled with an artificial neural network (ANN) algorithm.
  • SELDI-TOF-MS protein fingerprinting of serum from 105 brain tumor patients and healthy individuals, included 28 patients with glioma (Astrocytoma I-IV), 37 patients with brain benign tumor, and 40 age-matched healthy individuals.
  • An accuracy of 95.7%, sensitivity of 88.9%, specificity of 100%, positive predictive value of 90% and negative predictive value of 100% were obtained in a blinded test set comparing gliomas patients with healthy individuals; an accuracy of 86.4%, sensitivity of 88.9%, specificity of 84.6%, positive predictive value of 90% and negative predictive value of 85.7% were obtained when patient's gliomas was compared with benign brain tumor.
  • The high sensitivity and specificity achieved by the use of selected biomarkers showed great potential application for the discrimination of gliomas patients from healthy individuals and gliomas from brain benign tumors.
  • [MeSH-major] Astrocytoma / blood. Astrocytoma / diagnosis. Biomarkers, Tumor / blood. Brain Neoplasms / blood. Brain Neoplasms / diagnosis. Diagnosis, Computer-Assisted / methods. Neoplasm Proteins / blood. Peptide Mapping / methods

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Pain. 2003 Apr;102(3):251-6 [12670666.001]
  • [Cites] Curr Med Chem. 2003 May;10(10):831-43 [12678686.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s [12743135.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):267-79 [12781425.001]
  • [Cites] Curr Pharm Biotechnol. 2004 Feb;5(1):45-67 [14965209.001]
  • [Cites] Curr Opin Biotechnol. 2004 Feb;15(1):24-30 [15102462.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1164-77 [10786889.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Bioinformatics. 2002 Mar;18(3):395-404 [11934738.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1160-9 [12142368.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2541-52 [12171882.001]
  • (PMID = 15593384.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Letter; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1390751
  •  go-up   go-down


Advertisement
4. McCarthy BJ, Schellinger KA, Propp JM, Kruchko C, Malmer B: A case for the worldwide collection of primary benign brain tumors. Neuroepidemiology; 2009;33(3):268-75
figshare. supplemental materials - Supporting Data and Materials for the article .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case for the worldwide collection of primary benign brain tumors.
  • BACKGROUND: Incidence data on malignant tumors are reported by the International Agency for Research on Cancer, with 189,485 new malignant brain tumors globally in 2002.
  • However, collection and reporting of benign brain tumors are not universal.
  • The objective here is to encourage the collection of primary benign brain tumors worldwide.
  • METHODS: Worldwide numbers of primary benign brain tumors were estimated through published articles and cancer registry reports presenting directly or indirectly reported benign incidence rates or frequencies for regions or countries.
  • RESULTS: An estimated 186,678 benign brain tumors were diagnosed worldwide in 2002.
  • The estimated numbers of benign brain tumors were higher in females than males (105,918 vs. 80,759).
  • Since many countries do not report primary benign brain tumors, the incidence rate estimates vary significantly by region.
  • CONCLUSIONS: This is the first survey to assess worldwide numbers of benign brain tumors.
  • However, the estimated number of benign brain tumors approximately equals, and could exceed, the number of malignant brain tumors globally.
  • Registration of primary benign brain histologies in different geographical areas and ethnicities could provide clues to the underlying causes of these tumors.
  • [MeSH-major] Brain Neoplasms / epidemiology. Global Health

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - International Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19648771.001).
  • [ISSN] 1423-0208
  • [Journal-full-title] Neuroepidemiology
  • [ISO-abbreviation] Neuroepidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 57
  •  go-up   go-down


5. McCall T, Chin SS, Salzman KL, Fults DW: Tuberous sclerosis: a syndrome of incomplete tumor suppression. Neurosurg Focus; 2006;20(1):E3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberous sclerosis: a syndrome of incomplete tumor suppression.
  • The latter is a benign brain tumor of mixed neuronal and glial origin.
  • [MeSH-major] Hamartoma / complications. Tuberous Sclerosis / etiology. Tuberous Sclerosis / genetics. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Animals. Brain Neoplasms / complications. Brain Neoplasms / genetics. Humans. Models, Biological

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16459993.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein
  • [Number-of-references] 92
  •  go-up   go-down


6. Zhou GF, Wang XY, Huang MP: [BOLD-fMRI in sensory area and motor hand functional area with brain tumor in the central area]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Jul;33(7):576-81
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [BOLD-fMRI in sensory area and motor hand functional area with brain tumor in the central area].
  • OBJECTIVE: To explore the geomorphological performance, the characteristics of volume, and the largest signal intension of blood oxygenation level dependent functional magnetic resonance imaging (BOLD-fMRI) in brain tumors located in or closed to the central area.
  • METHODS: We recruited 13 normal volunteers and 31(13 benign tumors and 18 malignant tumors) patients with brain tumor located in or closed to the central area, to examine both side hand motor and tactile function by BOLD-fMRI and obtained the activation map and its superposition image with T1 imaging, the volume, and the largest signal intension of the functional area by SPM software which manipulated the raw data in the off-line work station.
  • There was difference in the activated signal pixel number and the largest signal intension of the functional area between the benign brain tumors, malignant brain tumors, and the normal volunteers (P < 0.05).
  • The shape, anatomic location, the volume, and the largest signal intension of the functional area were changed in the patients with brain tumors.
  • CONCLUSION: BOLD-fMRI is a valid method to assess the pre-surgical risk of patients with brain tumors, which can get the volume, the largest signal intension, the basic shape,and the anatomic location of the functional area.
  • [MeSH-major] Brain Neoplasms / physiopathology. Hand / physiopathology. Magnetic Resonance Imaging / methods. Motor Cortex / physiopathology. Somatosensory Cortex / physiopathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18667768.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


7. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM: Epidemiology of intracranial meningioma. Neurosurgery; 2005 Dec;57(6):1088-95; discussion 1088-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are the most frequently reported primary intracranial neoplasms, accounting for approximately 25% of all such lesions diagnosed in the United States.
  • Few studies have examined the risk factors associated with a diagnosis of meningioma with two categories of exposure, hormones (both endogenous and exogenous) and radiation, most strongly associated with meningioma risk.
  • Recent legislation passed in the United States (The Benign Brain Tumor Cancer Registries Amendment Act [H.R.
  • 5204]) mandates registration of benign brain tumors such as meningioma.
  • The increased emphasis on research dedicated to the study of brain tumors coupled with the advent of new tools in genetic and molecular epidemiology make the current era an ideal time to advance knowledge for intracranial meningioma.

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16331155.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R25 CA089017; United States / NCI NIH HHS / CA / 5R25-CA089017-03; United States / NCI NIH HHS / CA / P50-CA097257; United States / NCI NIH HHS / CA / R01-CA52689
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 76
  •  go-up   go-down


8. Sundgren PC, Cao Y: Brain irradiation: effects on normal brain parenchyma and radiation injury. Neuroimaging Clin N Am; 2009 Nov;19(4):657-68
MedlinePlus Health Information. consumer health - Diagnostic Imaging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain irradiation: effects on normal brain parenchyma and radiation injury.
  • Radiation therapy is a major treatment modality for malignant and benign brain tumors.
  • Concerns of radiation effects on the brain tissue and neurocognitive function and quality of life increase as survival of patients treated for brain tumors improves.
  • In this article, the clinical and neurobehavioral symptoms and signs of radiation-induced brain injury, possible histopathology, and the potential of functional, metabolic, and molecular imaging as a biomarker for assessment and prediction of neurotoxicity after brain irradiation and imaging findings in radiation necrosis are discussed.
  • [MeSH-major] Brain / radiation effects. Brain Injuries / diagnosis. Brain Injuries / etiology. Diagnostic Imaging / methods. Radiation Injuries / diagnosis. Radiation Injuries / etiology. Radiotherapy, Conformal / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19959011.001).
  • [ISSN] 1557-9867
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS064973
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS167505; NLM/ PMC5000393
  •  go-up   go-down


9. Mainio A, Hakko H, Niemelä A, Koivukangas J, Räsänen P: Gender difference in relation to depression and quality of life among patients with a primary brain tumor. Eur Psychiatry; 2006 Apr;21(3):194-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender difference in relation to depression and quality of life among patients with a primary brain tumor.
  • OBJECTIVE: We studied the relationship between depressive symptoms and quality of life (QOL) as well as functional status in primary brain tumor patients at recurrent measurements.
  • Differences in QOL between depressive and non-depressive samples by gender were controlled for tumor characteristics and patients' psychosocial factors.
  • MATERIALS AND METHODS: The data consisted of 77 patients with a primary brain tumor, 30 males and 47 females.
  • Depression of the patients was assessed by Beck Depression Inventory (BDI) and Crown-Crisp Experiential Index (CCEI), functional status by Karnofsky Performance scale (KPS) and QOL by Sintonen's 15D before tumor operation as well as at 3 months and at 1 year from surgical operation of the tumor.
  • Depressive patients with a benign brain tumor had significantly worse QOL versus non-depressive ones.
  • DISCUSSION AND CONCLUSION: Decreased QOL was strongly related to depression, especially among patients with a benign brain tumor.
  • [MeSH-major] Brain Neoplasms / psychology. Depressive Disorder / psychology. Glioma / psychology. Patients / psychology. Quality of Life / psychology

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140507.001).
  • [ISSN] 0924-9338
  • [Journal-full-title] European psychiatry : the journal of the Association of European Psychiatrists
  • [ISO-abbreviation] Eur. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Knisely JP, Linskey ME: Less common indications for stereotactic radiosurgery or fractionated radiotherapy for patients with benign brain tumors. Neurosurg Clin N Am; 2006 Apr;17(2):149-67, vii
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Less common indications for stereotactic radiosurgery or fractionated radiotherapy for patients with benign brain tumors.
  • Microsurgical resection remains the mainstay of treatment for truly benign brain tumors that can be safely resected because of the potential for permanent cure with most histologic findings, including most of the histologic findings discussed in this article.
  • Physicians must keep in mind the indolent nature of many of the benign brain tumors and realize that many patients are likely to live out normal life spans if tumor control is achieved.
  • Therefore, it is not sufficient simply to consider local tumor control rates and short-term toxicity risks when choosing between surgery, stereotactic radiosurgery, and fractionated radiotherapy.
  • For benign brain tumors, these decisions may have consequences that last for decades.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Patient Selection
  • [MeSH-minor] Astrocytoma / diagnosis. Astrocytoma / radiotherapy. Astrocytoma / surgery. Chordoma / diagnosis. Chordoma / radiotherapy. Chordoma / surgery. Dose Fractionation. Glomus Tumor / diagnosis. Glomus Tumor / radiotherapy. Glomus Tumor / surgery. Humans. Magnetic Resonance Imaging. Neurocytoma / diagnosis. Neurocytoma / radiotherapy. Neurocytoma / surgery. Paraganglioma / diagnosis. Paraganglioma / radiotherapy. Paraganglioma / surgery. Paraganglioma, Extra-Adrenal / diagnosis. Paraganglioma, Extra-Adrenal / radiotherapy. Paraganglioma, Extra-Adrenal / surgery. Pinealoma / diagnosis. Pinealoma / radiotherapy. Pinealoma / surgery. Radiosurgery / methods. Skull Base Neoplasms / diagnosis. Skull Base Neoplasms / radiotherapy. Skull Base Neoplasms / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793507.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 148
  •  go-up   go-down


11. Jagannathan J, Kanter AS, Sheehan JP, Jane JA Jr, Laws ER Jr: Benign brain tumors: sellar/parasellar tumors. Neurol Clin; 2007 Nov;25(4):1231-49, xi
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign brain tumors: sellar/parasellar tumors.
  • Neoplasms of the sellar region include pituitary adenomas, craniopharyngiomas, Rathke's cleft cysts, and, less commonly, meningiomas, germinomas, and hamartomas.
  • The diagnosis of sellar lesions involves a multidisciplinary effort; detailed endocrinologic, ophthalmologic, and neurologic tests are critical.
  • The management of pituitary tumors varies.
  • For most tumors, transsphenoidal resection remains the mainstay of treatment.
  • [MeSH-major] Brain Neoplasms / pathology. Pituitary Neoplasms / pathology. Sella Turcica / pathology
  • [MeSH-minor] Acromegaly / diagnosis. Chemotherapy, Adjuvant. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Pituitary ACTH Hypersecretion / diagnosis. Pituitary ACTH Hypersecretion / etiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964033.001).
  • [ISSN] 0733-8619
  • [Journal-full-title] Neurologic clinics
  • [ISO-abbreviation] Neurol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 69
  •  go-up   go-down


12. Cozzi L, Clivio A, Vanetti E, Nicolini G, Fogliata A: Comparative planning study for proton radiotherapy of benign brain tumors. Strahlenther Onkol; 2006 Jul;182(7):376-81
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative planning study for proton radiotherapy of benign brain tumors.
  • Twelve cases of "benign" brain tumors were considered (meningiomas, neurinomas, and hypophyseal adenomas).
  • Organs at risk included chiasm, brainstem, eyes and optic nerves as well as the not otherwise specified healthy brain tissue in view of long-term toxicity.
  • Plans designed with the spot-scanning technique presented the minimum involvement of healthy tissue (e. g., the lowest maximum significant dose to healthy brain [25.6 Gy] or the lowest conformity index [CI(95) = 1.3], between 38% and 46% lower than for the other techniques).
  • [MeSH-major] Brain Neoplasms / radiotherapy. Protons / therapeutic use. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Computer-Assisted / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826355.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


13. Kaynar MY, Sanus GZ, Hnimoglu H, Kacira T, Kemerdere R, Atukeren P, Gumustas K, Canbaz B, Tanriverdi T: Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma. J Clin Neurosci; 2008 Sep;15(9):1036-42
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma.
  • There was no statistically significant difference between the two types of tumor (p=0.264).
  • These findings indicate that HIF-1alpha is elevated in both TM and GBM, suggesting that although hypoxia is one of the most important and powerful stimuli for HIF-1alpha elevation and consequently angiogenesis, other mechanisms may play roles in HIF-1alpha stimulation in benign brain tumors such as TM.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioblastoma / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Anoxia / diagnosis. Anoxia / metabolism. Anoxia / physiopathology. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Cell Hypoxia / physiology. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neovascularization, Pathologic / etiology. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / physiopathology. Predictive Value of Tests. Up-Regulation / physiology

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18621534.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  •  go-up   go-down


14. Shrieve DC: Basic principles of radiobiology applied to radiotherapy of benign intracranial tumors. Neurosurg Clin N Am; 2006 Apr;17(2):67-78, v
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basic principles of radiobiology applied to radiotherapy of benign intracranial tumors.
  • The use of ionizing radiation in the treatment of benign intracranial tumors may involve one of several types of ionizing radiation given as single-fraction radiosurgery or fractionated radiotherapy.
  • This article discusses the basic radiobiologic principles applicable to radiotherapy of benign brain tumors.
  • [MeSH-major] Brain / radiation effects. Brain Neoplasms / radiotherapy. Radiobiology / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793500.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Hardell L, Carlberg M, Hansson Mild K: Case-control study on cellular and cordless telephones and the risk for acoustic neuroma or meningioma in patients diagnosed 2000-2003. Neuroepidemiology; 2005;25(3):120-8
MedlinePlus Health Information. consumer health - Acoustic Neuroma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a case-control study on the use of cellular and cordless telephones and the risk for brain tumors.
  • We report the results for benign brain tumors with data from 413 cases (89% response rate), 305 with meningioma, 84 with acoustic neuroma, 24 with other types and 692 controls (84% response rate).
  • [MeSH-major] Cell Phones / utilization. Meningeal Neoplasms / etiology. Meningioma / etiology. Neuroma, Acoustic / etiology

  • Genetic Alliance. consumer health - Acoustic Neuroma.
  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 15956809.001).
  • [ISSN] 0251-5350
  • [Journal-full-title] Neuroepidemiology
  • [ISO-abbreviation] Neuroepidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


16. Yang Y, Shao N, Luo G, Li L, Nilsson-Ehle P, Xu N: Relationship between PTEN gene expression and differentiation of human glioma. Scand J Clin Lab Invest; 2006;66(6):469-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor-adjacent normal tissues and benign brain tumors were used as controls.
  • RESULTS: PTEN mRNA levels were significantly lower in the glioma tissues than in the benign brain tumors and tumor-adjacent normal tissues, whereas there were no statistical differences between benign brain tumor and the tumor-adjacent normal tissues.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Glioma / genetics. Glioma / pathology. PTEN Phosphohydrolase / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Astrocytoma / pathology. Child. Female. Gene Expression. Genes, Tumor Suppressor. Glioblastoma / genetics. Glioblastoma / pathology. Glyceraldehyde-3-Phosphate Dehydrogenases / genetics. Humans. Male. Meningioma / genetics. Meningioma / pathology. Middle Aged. Mutation. Neuroma, Acoustic / genetics. Neuroma, Acoustic / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000554.001).
  • [ISSN] 0036-5513
  • [Journal-full-title] Scandinavian journal of clinical and laboratory investigation
  • [ISO-abbreviation] Scand. J. Clin. Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


17. Lu-Emerson C, Plotkin SR: The Neurofibromatoses. Part 1: NF1. Rev Neurol Dis; 2009;6(2):E47-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The neurofibromatoses, including neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis, comprise a group of genetically distinct disorders of the nervous system unified by the predisposition to nerve sheath tumors.
  • NF1 is the most common neurogenetic disorder, with a birth incidence of 1 in 3000.
  • The hallmark lesion of NF1 is the neurofibroma, a benign tumor derived from the nerve sheath and composed of a mixture of proliferating Schwann cells, fibroblasts, mast cells, and pericytes.
  • [MeSH-major] Bone and Bones / pathology. Nervous System / pathology. Neurofibromatosis 1 / diagnosis. Neurofibromatosis 1 / genetics. Skin / pathology
  • [MeSH-minor] Brain / pathology. Brain / physiopathology. Cafe-au-Lait Spots / genetics. Cafe-au-Lait Spots / pathology. Cafe-au-Lait Spots / physiopathology. Eye / pathology. Eye / physiopathology. Genes, Tumor Suppressor / physiology. Humans. Neurofibromatoses / genetics. Neurofibromatoses / pathology. Neurofibromatoses / physiopathology. Peripheral Nervous System / pathology. Peripheral Nervous System / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19587630.001).
  • [ISSN] 1949-4378
  • [Journal-full-title] Reviews in neurological diseases
  • [ISO-abbreviation] Rev Neurol Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


18. Fraser MM, Bayazitov IT, Zakharenko SS, Baker SJ: Phosphatase and tensin homolog, deleted on chromosome 10 deficiency in brain causes defects in synaptic structure, transmission and plasticity, and myelination abnormalities. Neuroscience; 2008 Jan 24;151(2):476-88
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphatase and tensin homolog, deleted on chromosome 10 deficiency in brain causes defects in synaptic structure, transmission and plasticity, and myelination abnormalities.
  • The tumor-suppressor phosphatase with tensin homology (PTEN) is the central negative regulator of the PI3K pathway.
  • Germline PTEN mutations result in cancer predisposition, macrocephaly and benign hamartomas in many tissues, including Lhermitte-Duclos disease, a cerebellar growth disorder.
  • Electron microscopic evaluation revealed enlarged abnormal synaptic structures in the cerebral cortex and cerebellum.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1999 Nov 17;91(22):1922-32 [10564676.001]
  • [Cites] Neurosurg Rev. 1980;3(2):151-8 [7231686.001]
  • [Cites] Immunity. 2001 May;14(5):523-34 [11371355.001]
  • [Cites] J Neurochem. 2001 Aug;78(3):468-81 [11483649.001]
  • [Cites] Am J Med Genet. 2001 Aug 8;105(6):521-4 [11496368.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):396-403 [11726926.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):404-11 [11726927.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2186-9 [11691952.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):467-72 [11756682.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(14):5100-13 [12077339.001]
  • [Cites] Brain Res Brain Res Rev. 2002 Jun;39(1):29-54 [12086707.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):157-68 [12086874.001]
  • [Cites] Development. 2002 Jul;129(14):3513-22 [12091320.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Development. 2002 Sep;129(17):4159-70 [12163417.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):179-92 [12612653.001]
  • [Cites] Development. 2003 Apr;130(8):1691-700 [12620992.001]
  • [Cites] Hum Mutat. 2003 Sep;22(3):183-98 [12938083.001]
  • [Cites] Trends Cell Biol. 2003 Sep;13(9):478-83 [12946627.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):209-21 [14522255.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12923-8 [14534328.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14368-73 [14623952.001]
  • [Cites] Cell. 2003 Dec 26;115(7):893-904 [14697206.001]
  • [Cites] Science. 2004 Feb 20;303(5661):1179-81 [14976311.001]
  • [Cites] J Neurochem. 2004 Apr;89(1):109-18 [15030394.001]
  • [Cites] PLoS Biol. 2003 Dec;1(3):E59 [14691534.001]
  • [Cites] Oncogene. 2004 Apr 19;23(18):3151-71 [15094765.001]
  • [Cites] Science. 2004 Apr 30;304(5671):700-3 [15044753.001]
  • [Cites] J Clin Invest. 2004 Jun;113(12):1774-83 [15199412.001]
  • [Cites] J Neurosci. 2004 Jul 28;24(30):6724-32 [15282275.001]
  • [Cites] J Neurosurg. 1988 Oct;69(4):599-603 [3418394.001]
  • [Cites] Histol Histopathol. 1990 Jul;5(3):329-36 [1724930.001]
  • [Cites] Acta Neuropathol. 1992;84(5):570-3 [1462769.001]
  • [Cites] Nat Genet. 1998 Jul;19(3):223 [9662392.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):348-55 [9697695.001]
  • [Cites] Curr Biol. 1998 Oct 22;8(21):1169-78 [9799734.001]
  • [Cites] Am J Med Genet. 1998 Dec 4;80(4):399-402 [9856571.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1563-8 [9990064.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7773-9 [15520182.001]
  • [Cites] J Neurosci. 2004 Nov 3;24(44):9760-9 [15525761.001]
  • [Cites] Cell. 2005 Jan 14;120(1):123-35 [15652487.001]
  • [Cites] Glia. 2005 Mar;49(4):542-54 [15578654.001]
  • [Cites] J Neurochem. 2005 Apr;93(1):105-17 [15773910.001]
  • [Cites] Glia. 2005 May;50(3):247-57 [15739189.001]
  • [Cites] Acta Neuropathol. 1983;59(2):88-94 [6837278.001]
  • [Cites] J Med Genet. 2005 Apr;42(4):318-21 [15805158.001]
  • [Cites] J Cell Sci. 2005 Aug 15;118(Pt 16):3653-62 [16046480.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7426-34 [16288289.001]
  • [Cites] Nat Neurosci. 2005 Dec;8(12):1727-34 [16286931.001]
  • [Cites] J Neurosci. 2005 Dec 7;25(49):11288-99 [16339024.001]
  • [Cites] J Neurosci. 2005 Dec 7;25(49):11300-12 [16339025.001]
  • [Cites] Neurochem Int. 2006 Jan;48(2):114-23 [16239049.001]
  • [Cites] J Cell Sci. 2006 Mar 1;119(Pt 5):951-7 [16495486.001]
  • [Cites] Neuron. 2006 Mar 16;49(6):823-32 [16543131.001]
  • [Cites] Neuron. 2006 May 4;50(3):377-88 [16675393.001]
  • [Cites] J Biol Chem. 2006 Jul 7;281(27):18802-15 [16651266.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7429-37 [16885338.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):184-96 [16412571.001]
  • [Cites] J Neurosci. 2006 Oct 4;26(40):10199-208 [17021175.001]
  • [Cites] Nat Neurosci. 2006 Dec;9(12):1520-5 [17099708.001]
  • [Cites] Neurobiol Dis. 2007 Nov;28(2):184-96 [17714952.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):1031-7 [10980141.001]
  • (PMID = 18082964.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA096832-01A10004; United States / NCI NIH HHS / CA / CA096832; United States / NINDS NIH HHS / NS / R01 NS044172; United States / NINDS NIH HHS / NS / NS044172; United States / NCI NIH HHS / CA / P01 CA096832-05; United States / NCI NIH HHS / CA / P01 CA096832; United States / NCI NIH HHS / CA / CA096832-05; United States / NCI NIH HHS / CA / P01 CA096832-01A10004
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ NIHMS39023; NLM/ PMC2278004
  •  go-up   go-down


19. Takahashi H, Harada M, Kimura M, Kato H: Thymolipoma combined with hyperthyroidism discovered by neurological symptoms. Ann Thorac Cardiovasc Surg; 2007 Apr;13(2):114-7
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thymolipomas are rare slow-growing mediastinal thymic neoplasms.
  • Central nervous system disorder was suggested but no significant abnormalities were found on brain MR nor were there any neurological signs.
  • Several months later, neurological and systemic examinations on admission revealed hyperthyroidism and an anterior mediastinal tumor, 9.0x5.0x3.0 cm in size on chest CT films.
  • Neurologists recommended resection of the mediastinal tumor.
  • Malignancy could not be ruled out because of the irregularity of the tumor appearance on contrast-enhanced chest CT.
  • Furthermore, the tumor appeared to be attached to the ascending aorta, so cytological and/or pathological diagnosis by CT-guided needle biopsy before operation were contraindicated.
  • The pathological diagnosis was benign thymolipoma consisting of mature fatty tissue and thymic tissue structures with Hassall's corpuscles.
  • [MeSH-major] Hyperthyroidism / complications. Lipoma / complications. Thymus Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17505419.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Aoki T, Tashiro Y, Fujita K, Kajiwara M, Matsuda Y: [The evaluation of preoperative and postoperative frontal lobe functions in three operative cases of meningioma]. No Shinkei Geka; 2006 Feb;34(2):161-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report three cases of frontal meningioma with their pre- and post-operative evaluations of higher brain functions, especially of frontal lobe functions.
  • All of the cases showed the improvement of the frontal lobe functions after the tumor removal.
  • The evaluations of frontal lobe functions in benign brain tumors such as a meningioma are reported only in a few cases.
  • The evaluations of frontal lobe functions in the operative cases of benign brain tumors provide many interesting and valuable informations about frontal lobe functions.
  • So we must be more interest in evaluations in higher brain functions and accumulate cases for the further analysis of higher brain functions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485561.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Kouklakis G, Babali A, Gatopoulou A, Lirantzopoulos N, Efremidou E, Vathikolias K: Asymptomatic brain finding results on MRI in a patient with Crohn's disease: a case report. J Gastrointestin Liver Dis; 2009 Dec;18(4):479-81
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymptomatic brain finding results on MRI in a patient with Crohn's disease: a case report.
  • We report the case of a 39-year old man with Crohn's disease and an intracranial benign primary tumor, detected on MRI scan.
  • The patient, being enrolled in a research protocol, underwent brain MRI examination.
  • Whether this is an incidental finding on brain MRI or whether it might be linked to Crohn's disease development as an extraintestinal, neurological disorder remains unclear.
  • [MeSH-major] Brain / pathology. Crohn Disease / complications. Incidental Findings. Magnetic Resonance Imaging. Meningeal Neoplasms / etiology. Meningioma / pathology

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20076823.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


22. Budrukkar A, Jalali R, Dutta D, Sarin R, Devlekar R, Parab S, Kakde A: Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice. J Neurooncol; 2009 Dec;95(3):413-419
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice.
  • The aim of this article is to evaluate and assess the impact of various factors on quality of life (QOL) in adult patients with primary brain tumors seen consecutively in routine neurooncology practice.
  • Two hundred and fifty-seven adult patients, after undergoing surgical intervention and histologically proven primary brain neoplasms were registered in the NeuroOncology Clinic at our centre during 1 full calendar year.
  • The study included detailed neurological assessment, evaluation of QOL using EORTC questionnaire (QLQ-30) and specific Brain Cancer module (BN 20).
  • In the present analysis, QOL scores before starting adjuvant treatment were measured and impact of patient and tumor related factors were analyzed.
  • Baseline global QOL data of all patients (available in 243) was relatively low including in all histological tumor types.
  • Domains of future uncertainty, visual disorder, motor deficit, communication deficit, headache, seizures and drowsiness scores were 19.6, 18.2, 28.5, 30.7, 21, 31.8 and 16 (lower values better), respectively.
  • Patients with lower performance status (KPS < 70) had a lower global QOL (KPS >or= 80 vs. <or= 70; 37 vs. 67; p = 0.001) including in all histological types of high-grade gliomas (HGG) (p = 0.005), low-grade gliomas (LGG) (p = 0.04) and benign tumors (p = <0.001).
  • Tumor type is an important patient related factor that influences baseline global scores (LGG vs. HGG 62 and 52; p = 0.015).
  • Type of surgery (biopsy/complete excision) (p = 0.284) and site of tumor (p = 0.309) did not show any impact on QOL score.
  • Patients with primary brain tumours before starting adjuvant therapy have relatively low baseline quality of life scores, especially in lower economic and literacy strata.
  • Patients with malignant tumors and poor performance status had significantly lower QOL scores even before starting adjuvant treatment.
  • [MeSH-major] Brain Neoplasms / physiopathology. Brain Neoplasms / therapy. Glioma / physiopathology. Glioma / therapy. Outpatient Clinics, Hospital. Quality of Life
  • [MeSH-minor] Adenoma / physiopathology. Adenoma / therapy. Adolescent. Adult. Educational Status. Female. Health Status. Humans. India. Karnofsky Performance Status. Male. Meningeal Neoplasms / physiopathology. Meningeal Neoplasms / therapy. Middle Aged. Pituitary Neoplasms / physiopathology. Pituitary Neoplasms / therapy. Prospective Studies. Surveys and Questionnaires. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2002 Sep;38(14):1824-31 [12204663.001]
  • [Cites] Lancet. 2002 Nov 2;360(9343):1361-8 [12423981.001]
  • [Cites] Qual Life Res. 1996 Feb;5(1):139-50 [8901377.001]
  • [Cites] J Neurooncol. 2009 Aug;94(1):103-10 [19255726.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12 ):937-44 [16321761.001]
  • [Cites] J Neurooncol. 2008 Mar;87(1):111-4 [18004503.001]
  • [Cites] Neuro Oncol. 2000 Oct;2(4):221-8 [11265231.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):283-91 [16163448.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] J Cancer Res Ther. 2006 Oct-Dec;2(4):166-70 [17998699.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):139-44 [9440735.001]
  • [Cites] J Neurooncol. 2008 Dec;90(3):321-8 [18704269.001]
  • [Cites] BMC Cancer. 2007 Jan 25;7:18 [17254350.001]
  • (PMID = 19548070.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Wu C, Yen YS, Ho DM, Guo W: Primary neurocytoma in the spinal cord. A case report. Neuroradiol J; 2006 Nov 30;19(5):672-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Central neurocytoma is defined as an intraventricular benign brain tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24351271.001).
  • [ISSN] 1971-4009
  • [Journal-full-title] The neuroradiology journal
  • [ISO-abbreviation] Neuroradiol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Settin A, Ali N, Salem FK: Cytokine gene polymorphisms in Egyptian cases with brain tumors. Egypt J Immunol; 2008;15(2):15-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine gene polymorphisms in Egyptian cases with brain tumors.
  • Cytokines are proposed to play important roles in brain tumor biology as well as neurodegeneration or impaired neuronal function.
  • To evaluate the association of polymorphisms of cytokine genes with brain tumors in Egyptian patients.
  • This study included 45 cases affected by brain tumors.
  • Their median age was 45, diagnosed as 24 benign cases and 21 malignant cases, and their sex included 20 males and 25 females.
  • Cases affected with benign brain tumors, showed a significant higher frequency of IL-10(-1082) A/A genotype (OR = 8.04, P < 0.001), IL-6(-174) C/C genotype (OR = 6.3, P < 0.001) and TNF-alpha(-308) A/A (OR = 4.7, P < 0.05) with a significant lower frequency of IL-10(-1082) G/A genotype (OR = 0.1, P < 0.001), IL-6(-174) G/C (OR = 0.2, P = 0.001) and TNF-alpha(-308) G/A was found significantly low among the same groups (OR = 0.2, P < 0.001) compared to controls.
  • The frequency of cytokines genotype and allele in malignant brain cases and controls.
  • Comparing studied genotype frequencies among benign and malignant brain tumor cases no significant difference was found in the frequencies of all studied genotypes and alleles with a non significant trend for the benign cases to have higher frequency of IL-10(-1082) AA genotype.
  • In conclusion, cytokine gene polymorphisms have a certain pattern among brain tumor cases and can be considered a genetic marker of potential value in counseling and management.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306684.001).
  • [ISSN] 1110-4902
  • [Journal-full-title] The Egyptian journal of immunology
  • [ISO-abbreviation] Egypt J Immunol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


25. Hu H, Yao HT, Zhang WP, Zhang L, Ding W, Zhang SH, Chen Z, Wei EQ: Increased expression of aquaporin-4 in human traumatic brain injury and brain tumors. J Zhejiang Univ Sci B; 2005 Jan;6(1):33-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of aquaporin-4 in human traumatic brain injury and brain tumors.
  • OBJECTIVE: To characterize the expression of aquaporin-4 (AQP4), one of the aquaporins (AQPs), in human brain specimens from patients with traumatic brain injury or brain tumors.
  • METHODS: Nineteen human brain specimens were obtained from the patients with traumatic brain injury, brain tumors, benign meningioma or early stage hemorrhagic stroke.
  • MRI or CT imaging was used to assess brain edema.
  • CONCLUSION: AQP4 expression increases in human brains after traumatic brain injury, within brain-derived tumors, and around brain tumors.
  • [MeSH-major] Aquaporins / metabolism. Brain Edema / metabolism. Brain Edema / pathology. Brain Injuries / metabolism. Brain Injuries / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2000 Feb;6(2):159-63 [10655103.001]
  • [Cites] Brain Res Mol Brain Res. 2000 May 31;78(1-2):131-7 [10891592.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):262-5 [11796780.001]
  • [Cites] Brain Res Brain Res Rev. 2002 Jun;39(1):55-73 [12086708.001]
  • [Cites] J Anat. 2002 Jun;200(6):617-27 [12162729.001]
  • [Cites] J Neurosurg. 2003 Mar;98(3):565-9 [12650429.001]
  • [Cites] Acta Neuropathol. 2003 Aug;106(2):121-4 [12715185.001]
  • [Cites] J Biol Chem. 1988 Oct 25;263(30):15634-42 [3049610.001]
  • [Cites] J Neurosci. 1997 Jan 1;17(1):171-80 [8987746.001]
  • [Cites] J Biol Chem. 1997 Jun 27;272(26):16140-6 [9195910.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11981-6 [9751776.001]
  • (PMID = 15593389.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / AQP4 protein, human; 0 / Aquaporin 4; 0 / Aquaporins; 0 / Biomarkers
  • [Other-IDs] NLM/ PMC1390756
  •  go-up   go-down


26. Sasikala M, Kumaravel N: A wavelet-based optimal texture feature set for classification of brain tumours. J Med Eng Technol; 2008 May-Jun;32(3):198-205
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A wavelet-based optimal texture feature set for classification of brain tumours.
  • In this work, the classification of brain tumours in magnetic resonance images is studied by using optimal texture features.
  • These features are used to classify three sets of brain images - normal brain, benign tumour and malignant tumour.
  • Each selected brain region of interest is characterized with both its energy and texture features extracted from the selected high frequency subband.
  • [MeSH-major] Algorithms. Artificial Intelligence. Brain Neoplasms / diagnosis. Image Interpretation, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Pattern Recognition, Automated / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18432467.001).
  • [ISSN] 0309-1902
  • [Journal-full-title] Journal of medical engineering & technology
  • [ISO-abbreviation] J Med Eng Technol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Mnif I, Chaker M, Daoud E, Ben Mahfoudh K, Mnif Z, Mnif J: [Central neurocytoma: three case reports]. J Neuroradiol; 2008 Mar;35(1):56-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Neurocytome central: à propos de trois observations.
  • Central neurocytoma is classically recognized as an intraventricular benign brain tumour.
  • Histologically, central neurocytoma presents remarkable likeness characteristics to oligodendroglioma, but immunohistochemical study distinguishes this tumour.
  • Imaging appearances (CT, MRI) raise the diagnosis and immunohistochemical study confirm it.
  • The purpose of our work is to assess the value of imaging (CT, MRI) in the diagnosis of central neurocytoma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neurocytoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17617462.001).
  • [ISSN] 0150-9861
  • [Journal-full-title] Journal of neuroradiology. Journal de neuroradiologie
  • [ISO-abbreviation] J Neuroradiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


28. Kubo O, Chernov M, Izawa M, Hayashi M, Muragaki Y, Maruyama T, Hori T, Takakura K: Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation? Minim Invasive Neurosurg; 2005 Dec;48(6):334-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation?
  • Malignant transformation of benign neoplasm after radiosurgery is usually diagnosed based on the initial presence of benign tumor, its exposure to ionizing radiation, elapsed time from radiation exposure to malignant progression, and different histological characteristics or growth rate of the regrowing tumor comparing with those originally treated.
  • Three presented cases fulfilled these diagnostic criteria; however, it seems that progression of the tumors (schwannoma, meningioma, chordoma) resulted from the natural course of the disease, rather than represented side effects of gamma knife radiosurgery.
  • Evaluation of the proliferative potential of the benign neoplasm before radiosurgical treatment either directly, if tumor sampling is available, or indirectly, by calculation of the tumor growth rate and/or analysis of the data of the metabolic imaging (PET, MRS) is important for identification of "aggressive" subtypes, precise prediction of prognosis, and confirmation of the radiation-induced malignant transformation in cases of tumor regrowth.
  • [MeSH-major] Brain Neoplasms / surgery. Cell Transformation, Neoplastic / radiation effects. Chordoma / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasms, Radiation-Induced / physiopathology. Neurilemmoma / surgery. Radiosurgery / adverse effects
  • [MeSH-minor] Adult. Brain Diseases / surgery. Cell Proliferation. Female. Humans. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432782.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


29. Health Quality Ontario: Functional brain imaging: an evidence-based analysis. Ont Health Technol Assess Ser; 2006;6(22):1-79

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional brain imaging: an evidence-based analysis.
  • OBJECTIVE: The objective of this analysis is to review a spectrum of functional brain imaging technologies to identify whether there are any imaging modalities that are more effective than others for various brain pathology conditions.
  • This evidence-based analysis reviews magnetoencephalography (MEG), magnetic resonance spectroscopy (MRS), positron emission tomography (PET), and functional magnetic resonance imaging (fMRI) for the diagnosis or surgical management of the following conditions: Alzheimer's disease (AD), brain tumours, epilepsy, multiple sclerosis (MS), and Parkinson's disease (PD).
  • In Ontario, there will be an estimated 950 new cases and 580 deaths due to brain cancer in 2006.
  • Treatments for brain tumours include surgery and radiation therapy.
  • Computed tomography (CT) and magnetic resonance imaging (MRI) may not distinguish between radiation effects and resistant tissue, creating a potential role for functional brain imaging.
  • Epilepsy is a chronic disorder that provokes repetitive seizures.
  • Surgical resection of the seizure foci may be considered in these patients, and functional brain imaging may play a role in localizing the seizure foci.
  • Parkinson's disease is the most prevalent movement disorder; it affects an estimated 100,000 Canadians.
  • Functional brain imaging may provide an objective measure of disease progression, differentiation between parkinsonian syndromes, and response to therapy.
  • THE TECHNOLOGY BEING REVIEWED: FUNCTIONAL BRAIN IMAGING: Functional brain imaging technologies measure blood flow and metabolism.
  • Positron emission tomography and MRS identify abnormalities in brain tissues.
  • The former measures abnormalities through uptake of radiotracers in the brain, while the latter measures chemical shifts in metabolite ratios to identify abnormalities.
  • The potential role of functional MRI (fMRI) is to identify the areas of the brain responsible for language, sensory and motor function (sensorimotor cortex), rather than identifying abnormalities in tissues.
  • Magnetoencephalography measures magnetic fields of the electric currents in the brain, identifying aberrant activity.
  • Those criteria included the following: Full reports of systematic reviews, randomized controlled trials (RCTs), cohort-control studies, prospective cohort studies (PCS'), and retrospective studies.Sample sizes of at least 20 patients (≥ 10 with condition being reviewed).English-language studies.Human studies.Any age.STUDYING AT LEAST ONE OF THE FOLLOWING: fMRI, PET, MRS, or MEG.Functional brain imaging modality must be compared with a clearly defined reference standard.MUST REPORT AT LEAST ONE OF THE FOLLOWING OUTCOMES: sensitivity, specificity, accuracy, positive predictive value (PPV), receiver operating characteristic curve, outcome measuring impact on diagnostic testing, treatment, patient health, or cost.
  • SUMMARY OF FINDINGS: There is evidence to indicate that PET can accurately diagnose AD; however, at this time, there is no evidence to suggest that a diagnosis of AD with PET alters the clinical outcomes of patients.
  • The addition of MRS or O-(2-(18)F-Fluoroethyl)-L-Tyrosine (FET)-PET to gadolinium (Gd)-enhanced MRI for distinguishing malignant from benign tumours during primary diagnosis may provide a higher specificity than Gd-enhanced MRI alone.
  • The clinical utility of additional imaging in patients to distinguish malignant from benign tumours is unclear, because patients with a suspected brain tumour will likely undergo a biopsy despite additional imaging results.
  • There may be a role for fMRI in the identification of surgical candidates for tumour resection; however, this requires further research.
  • Positron emission tomography has high sensitivity and specificity in the diagnosis of PD and the differential diagnosis of parkinsonian syndromes; however, it is unclear at this time if the addition of PET in the diagnosis of these conditions contributes to the treatment and clinical outcomes of patients.
  • There is limited clinical utility of functional brain imaging in the management of patients with MS at this time.
  • Diagnosis of MS is established through clinical history, evoked potentials, and MRI.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Epilepsia. 2004 Dec;45(12):1623-9 [15571521.001]
  • [Cites] Epilepsia. 2005 Jan;46(1):59-68 [15660769.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):653-9 [15711980.001]
  • [Cites] J Neurosurg. 2005 Feb;102(2):318-27 [15739561.001]
  • [Cites] Brain. 2005 May;128(Pt 5):1188-98 [15758038.001]
  • [Cites] Epilepsia. 2005 May;46(5):688-95 [15857434.001]
  • [Cites] Neuroimage. 2005 Jul 1;26(3):912-21 [15955501.001]
  • [Cites] Radiology. 2005 Jul;236(1):247-53 [15987978.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2005 Aug;76(8):1152-7 [16024896.001]
  • [Cites] Ann Neurol. 2005 Oct;58(4):525-32 [16037972.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Nov;32(11):1311-6 [16078061.001]
  • [Cites] J Clin Neurophysiol. 2005 Aug;22(4):231-7 [16093894.001]
  • [Cites] Neuroradiology. 2005 Nov;47(11):826-34 [16142479.001]
  • [Cites] Mult Scler. 2005 Oct;11(5):516-9 [16193887.001]
  • [Cites] J Nucl Med. 2005 Oct;46(10):1625-32 [16204712.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):200-9 [16228235.001]
  • [Cites] AJR Am J Roentgenol. 2005 Dec;185(6):1471-6 [16304000.001]
  • [Cites] J Nucl Med. 2005 Dec;46(12):1948-58 [16330557.001]
  • [Cites] Acta Radiol. 2005 Oct;46(6):599-609 [16334841.001]
  • [Cites] Lancet Neurol. 2006 Jan;5(1):75-86 [16361025.001]
  • [Cites] J Child Neurol. 2005 Nov;20(11):885-92 [16417858.001]
  • [Cites] Health Technol Assess. 2006 Feb;10(4):1-250, iii-iv [16487454.001]
  • [Cites] Acta Radiol. 2006 Feb;47(1):85-90 [16498938.001]
  • [Cites] Epilepsia. 2006 Feb;47(2):355-64 [16499760.001]
  • [Cites] Epilepsia. 2006 Mar;47(3):574-9 [16529624.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):801-9 [16550383.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Mar;27(3):475-87 [16551981.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2006 Mar;50(1):88-93 [16557208.001]
  • [Cites] BMJ. 2006 Apr 15;332(7546):875-84 [16565096.001]
  • [Cites] Int J Technol Assess Health Care. 2006 Spring;22(2):143-8 [16571188.001]
  • [Cites] Ann Neurol. 2006 May;59(5):835-42 [16634031.001]
  • [Cites] Am J Alzheimers Dis Other Demen. 2006 Mar-Apr;21(2):73-8 [16634461.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):904-11 [16741298.001]
  • [Cites] Radiology. 2006 Sep;240(3):793-802 [16857981.001]
  • [Cites] Ann Neurol. 2006 Aug;60(2):270 [16862582.001]
  • [Cites] Ann Neurol. 2006 Aug;60(2):271 [16862587.001]
  • [Cites] Neuroimage. 2006 Oct 1;32(4):1793-803 [16889984.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Aug;27(7):1404-11 [16908548.001]
  • [Cites] Radiology. 2006 Oct;241(1):213-22 [16908676.001]
  • [Cites] Epilepsia. 2006 Aug;47(8):1308-19 [16922875.001]
  • [Cites] Neurosurgery. 2006 Sep;59(3):493-510; discussion 510-1 [16955031.001]
  • [Cites] J Int Med Res. 2006 Jul-Aug;34(4):339-47 [16989488.001]
  • [Cites] J Neural Transm Suppl. 2006;(70):241-8 [17017536.001]
  • [Cites] Magn Reson Imaging. 2006 Nov;24(9):1131-42 [17071335.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4 [1564476.001]
  • [Cites] Med Decis Making. 1991 Apr-Jun;11(2):88-94 [1907710.001]
  • [Cites] Epilepsia. 1995 Mar;36(3):230-5 [7614905.001]
  • [Cites] CMAJ. 1994 Mar 15;150(6):899-913 [8131123.001]
  • [Cites] N Engl J Med. 1996 Mar 7;334(10):647-52 [8592530.001]
  • [Cites] Neurology. 1996 Apr;46(4):978-84 [8780076.001]
  • [Cites] Electroencephalogr Clin Neurophysiol Suppl. 1996;46:209-13 [9059795.001]
  • [Cites] J Image Guid Surg. 1995;1(6):339-47 [9080354.001]
  • [Cites] Epilepsia. 1997 Apr;38(4):452-60 [9118851.001]
  • [Cites] Epilepsia. 1998 Dec;39(12):1302-8 [9860065.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):73-9 [10389883.001]
  • [Cites] Epilepsia. 1999 Jul;40(7):931-41 [10403217.001]
  • [Cites] Neurology. 1999 Sep 22;53(5):938-45 [10496250.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Sep;20(8):1511-9 [10512239.001]
  • [Cites] Ann Neurol. 1999 Oct;46(4):627-33 [10514100.001]
  • [Cites] J Neurosurg. 1999 Nov;91(5):787-96 [10541236.001]
  • [Cites] Neuroimage. 1999 Dec;10(6):738-48 [10600419.001]
  • [Cites] Neurology. 2000 Jul 12;55(1):66-73 [10891908.001]
  • [Cites] J Comput Assist Tomogr. 2000 Nov-Dec;24(6):927-34 [11105714.001]
  • [Cites] Hum Brain Mapp. 2001 Mar;12(3):180-92 [11170309.001]
  • [Cites] Brain Tumor Pathol. 2000;17(2):57-64 [11210172.001]
  • [Cites] Epilepsia. 2001 Feb;42(2):282-6 [11240604.001]
  • [Cites] J Child Neurol. 2001 Feb;16(2):124-30 [11292218.001]
  • [Cites] Neurology. 2001 Sep 11;57(5):871-8 [11552019.001]
  • [Cites] Neurology. 2001 Oct 23;57(8):1497-9 [11673599.001]
  • [Cites] Eur J Neurol. 2001 Nov;8(6):573-7 [11784341.001]
  • [Cites] J Neurosurg. 2002 Oct;97(4):865-73 [12405375.001]
  • [Cites] J Am Geriatr Soc. 2003 Feb;51(2):258-64 [12558725.001]
  • [Cites] Neurology. 2003 Jun 10;60(11):1788-92 [12796532.001]
  • [Cites] TEC Bull (Online). 2003 Jun 3;20(2):1-3 [12854547.001]
  • [Cites] Brain. 2003 Nov;126(Pt 11):2396-405 [12876149.001]
  • [Cites] Neurology. 2003 Sep 9;61(5):699-701 [12963768.001]
  • [Cites] Neurosurg Rev. 2004 Jan;27(1):1-18; discussion 19-21 [14586764.001]
  • [Cites] Value Health. 2003 Sep-Oct;6(5):542-50 [14627060.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Jan;75(1):103-9 [14707317.001]
  • [Cites] Neurology. 2004 Mar 23;62(6):943-8 [15037697.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Aug;31(8):1128-35 [15042325.001]
  • [Cites] Radiology. 2004 Apr;231(1):73-80 [15068942.001]
  • [Cites] Clin Auton Res. 2004 Apr;14(2):84-91 [15095050.001]
  • [Cites] Lancet Neurol. 2004 May;3(5):284-90 [15099543.001]
  • [Cites] Neurosurgery. 2004 May;54(5):1111-7; discussion 1117-9 [15113465.001]
  • [Cites] J Neurosurg. 2004 May;100(5):867-76 [15137606.001]
  • [Cites] Epilepsia. 2004 Jun;45(6):641-9 [15144429.001]
  • [Cites] BMJ. 2004 Jun 19;328(7454):1490 [15205295.001]
  • [Cites] Clin Neurophysiol. 2004 Sep;115(9):2066-76 [15294209.001]
  • [Cites] Neurosurg Focus. 2003 Jul 15;15(1):E7 [15355009.001]
  • [Cites] Neurosurgery. 2004 Oct;55(4):904-14; discusssion 914-5 [15458599.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7163-70 [15534088.001]
  • [Cites] Clin Neurol Neurosurg. 2004 Dec;107(1):20-6 [15567548.001]
  • (PMID = 23074493.001).
  • [ISSN] 1915-7398
  • [Journal-full-title] Ontario health technology assessment series
  • [ISO-abbreviation] Ont Health Technol Assess Ser
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3379170
  •  go-up   go-down


30. Rosenfeld A, Listernick R, Charrow J, Goldman S: Neurofibromatosis type 1 and high-grade tumors of the central nervous system. Childs Nerv Syst; 2010 May;26(5):663-7
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type 1 and high-grade tumors of the central nervous system.
  • PURPOSE: Neurofibromatosis type 1 (NF1), a common genetic disorder, predisposes patients to the development of both benign and malignant tumors.
  • Although the most common central nervous system (CNS) tumor is a low-grade pilocytic astrocytoma of the optic pathway, there have been sporadic reports of NF1 patients with more aggressive CNS lesions.
  • METHODS: We conducted a retrospective review of all patients with NF1 and any CNS tumor being followed in the Children's Memorial Hospital NF1 Clinic.
  • RESULTS: Seven hundred forty patients with a diagnosis of NF1 were identified.
  • Of these, 145 (20%) patients had CNS tumors, 99 (68%) of whom had optic pathway tumors (OPTs).
  • Five patients (3%) were identified as having high-grade tumors, which consisted of anaplastic medulloblastoma (n = 1) and high-grade glioma (n = 4).
  • The mean age at diagnosis of NF1 was 2 years.
  • Currently, two patients are alive and receiving therapy at a mean of 10 months following diagnosis.
  • CONCLUSION: High-grade CNS tumors may occur in children with NF1.
  • Although tumors in NF patients are generally benign, clinicians should have a high index of suspicion of malignancy in patients whose tumors are in an unusual location or behave in an uncharacteristically aggressive manner.
  • [MeSH-major] Brain Neoplasms / complications. Neurofibromatosis 1 / complications

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2002 Sep 10;59(5):759-61 [12221173.001]
  • [Cites] Neurol Clin. 2002 Aug;20(3):841-65 [12432832.001]
  • [Cites] J Child Neurol. 2002 Aug;17(8):630-7; discussion 646-51 [12403562.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):759-67 [11005256.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):925-46, viii [17964021.001]
  • [Cites] Clin Cancer Res. 1997 Mar;3(3):473-8 [9815707.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):141-51 [11465394.001]
  • [Cites] Pediatr Neurol. 2005 Apr;32(4):221-8 [15797177.001]
  • [Cites] Neurocirugia (Astur). 2002 Apr;13(2):128-31 [12058604.001]
  • [Cites] Neurology. 1996 Jun;46(6):1652-60 [8649565.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2570-5 [16735710.001]
  • [Cites] Leukemia. 1993 Jun;7(6):912-5 [8388972.001]
  • [Cites] Neuropathol Appl Neurobiol. 2000 Aug;26(4):361-7 [10931370.001]
  • [Cites] Neurology. 2003 Nov 25;61(10):1397-400 [14638962.001]
  • (PMID = 19937438.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Rozmovits L, Khu KJ, Osman S, Gentili F, Guha A, Bernstein M: Information gaps for patients requiring craniotomy for benign brain lesion: a qualitative study. J Neurooncol; 2010 Jan;96(2):241-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Information gaps for patients requiring craniotomy for benign brain lesion: a qualitative study.
  • Twenty-five semi-structured interviews were conducted with ambulatory adult patients who had undergone surgery for a benign brain tumor, arteriovenous malformation, or unruptured aneurysm.

  • MedlinePlus Health Information. consumer health - Choosing a Doctor or Health Care Service.
  • MedlinePlus Health Information. consumer health - Talking With Your Doctor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] ANZ J Surg. 2001 Jan;71(1):24-6 [11167593.001]
  • [Cites] Heart. 2001 Dec;86(6):626-31 [11711453.001]
  • [Cites] BMJ. 2003 Nov 15;327(7424):1159-61 [14615345.001]
  • [Cites] Br Heart J. 1984 Oct;52(4):468-70 [6477788.001]
  • [Cites] J R Soc Med. 1994 Mar;87(3):149-52 [8158593.001]
  • [Cites] Neurosurgery. 2009 Jan;64(1):40-7; discussion 47 [19145155.001]
  • [Cites] Eur J Cardiothorac Surg. 2005 Sep;28(3):407-14 [16055340.001]
  • [Cites] Mayo Clin Proc. 2006 Mar;81(3):307-12 [16529133.001]
  • [Cites] J Med Ethics. 2006 Oct;32(10):612-6 [17012508.001]
  • [Cites] Int J Qual Health Care. 2007 Apr;19(2):113-9 [17277008.001]
  • [Cites] N Z Med J. 1998 Sep 11;111(1073):340-2 [9785548.001]
  • (PMID = 19575147.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / / MOP 77670
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2808535
  •  go-up   go-down


32. Todaro L, Christiansen S, Varela M, Campodónico P, Pallotta MG, Lastiri J, Sacerdote de Lustig E, Bal de Kier Joffé E, Puricelli L: Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J Neurooncol; 2007 Jun;83(2):135-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors.
  • We studied by Western blot the pattern of serum NCAM bands in patients with gliomas (n = 34), with brain metastasis of different primary cancers (n = 27) and with benign brain tumors (n = 22)] compared with healthy controls (n = 69).
  • A similar pattern was found in patients with brain metastasis or brain benign tumors, suggesting that the pattern of serum NCAM bands would be useful to detect brain tumor pathology.
  • Interestingly, we found that 9/12 patients with glioma showed a significant decrease in NCAM HMW/LMW ratio between 1-3 months after successful tumor removal.
  • Thus, serum NCAM could be a useful marker for monitoring treatment.NCAM expression was also analyzed at tissular level in 59 glioma sections from paraffined tumors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Glioma / metabolism. Neural Cell Adhesion Molecules / metabolism
  • [MeSH-minor] Adult. Aged. Brain / metabolism. Case-Control Studies. Female. Gene Expression Profiling. Humans. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Melanoma / metabolism. Melanoma / secondary. Middle Aged. Protein Isoforms. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Statistics, Nonparametric. Survival Analysis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1267-76 [9777989.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):217-28 [15674479.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):106-10 [9662259.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1991 Summer;3(3):330-3 [1821250.001]
  • [Cites] Prostate. 1997 Aug 1;32(3):214-20 [9254901.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Brain Res Mol Brain Res. 1999 Dec 10;74(1-2):69-82 [10640677.001]
  • [Cites] J Neurochem. 1989 Nov;53(5):1372-8 [2795005.001]
  • [Cites] Surgery. 2001 Nov;130(5):834-43 [11685193.001]
  • [Cites] Int J Dev Neurosci. 1993 Oct;11(5):681-90 [8116479.001]
  • [Cites] Int J Cancer. 1994 Jul 1;58(1):116-22 [8014007.001]
  • [Cites] Pancreas. 2001 Mar;22(2):122-5 [11249065.001]
  • [Cites] Int J Colorectal Dis. 2005 Jan;20(1):57-61 [15309466.001]
  • [Cites] Semin Cell Biol. 1992 Jun;3(3):189-97 [1623208.001]
  • [Cites] J Neurosci Res. 1995 May 1;41(1):49-64 [7674377.001]
  • [Cites] J Neurooncol. 2001 Feb;51(3):245-64 [11407596.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):2020-8 [9581848.001]
  • [Cites] Int J Dev Neurosci. 2000 Apr-Jun;18(2-3):193-9 [10715574.001]
  • [Cites] J Clin Pathol. 2005 Sep;58(9):978-80 [16126882.001]
  • [Cites] Neuropathol Appl Neurobiol. 1991 Jun;17(3):207-17 [1891065.001]
  • [Cites] J Cell Sci. 2002 Jan 15;115(Pt 2):283-92 [11839780.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1227-30 [9137477.001]
  • [Cites] Cell. 1988 Dec 23;55(6):955-64 [3203385.001]
  • [Cites] Br J Haematol. 2005 May;129(4):539-41 [15877737.001]
  • [Cites] J Zhejiang Univ Sci B. 2005 Jan;6(1):4-10 [15593384.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6364-70 [2400996.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38305-16 [16172115.001]
  • [Cites] J Neurosci Res. 1999 Jan 1;55(1):99-106 [9890438.001]
  • [Cites] Front Biosci. 2003 May 01;8:d900-11 [12700044.001]
  • [Cites] Prog Neurobiol. 1998 Aug;55(6):659-69 [9670224.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:425-56 [9442880.001]
  • [Cites] Curr Opin Oncol. 2004 Nov;16(6):607-13 [15627025.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):485-94 [16212813.001]
  • [Cites] Neuroimmunomodulation. 1997 Mar-Apr;4(2):57-61 [9483195.001]
  • [Cites] Histol Histopathol. 2003 Jan;18(1):207-16 [12507300.001]
  • [Cites] Oncology. 2005;69 Suppl 1:14-6 [16210871.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):415-21 [10821486.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(20):6942-6 [3863135.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):125-8 [12086870.001]
  • [Cites] Neurobiol Dis. 2004 Mar;15(2):387-93 [15006709.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):44-51 [11550301.001]
  • [Cites] Glycobiology. 2005 Sep;15(9):887-94 [15872150.001]
  • [Cites] Biol Psychiatry. 1998 May 1;43(9):680-6 [9583002.001]
  • [Cites] Acta Neurol Belg. 2004 Dec;104(4):148-53 [15742604.001]
  • [Cites] Cancer. 1998 May 15;82(10):1921-31 [9587126.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jan;65(1):1-11 [16410743.001]
  • (PMID = 17216340.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neural Cell Adhesion Molecules; 0 / Protein Isoforms
  •  go-up   go-down


33. Jozwiak J, Wlodarski P: Hamartin and tuberin modulate gene transcription via beta-catenin. J Neurooncol; 2006 Sep;79(3):229-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberous sclerosis, neurological genetic disorder characterized by the formation of benign tumors or hamartomas in multiple organ systems, is recently getting much attention.
  • Studies on tuberous sclerosis allowed identification of two tumor suppressor genes, TSC1 and TSC2, encoding proteins implicated in the disease: hamartin and tuberin, respectively.
  • [MeSH-major] Signal Transduction / physiology. Transcription, Genetic / physiology. Tumor Suppressor Proteins / metabolism. Wnt Proteins / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Animals. Brain Neoplasms / metabolism. Humans. Tuberous Sclerosis / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Neurosurg. 2000 Apr;32(4):187-91 [10940769.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8573-8 [15937108.001]
  • [Cites] J Cell Sci. 2002 Dec 15;115(Pt 24):4743-53 [12432063.001]
  • [Cites] Am J Hum Genet. 2001 Jan;68(1):64-80 [11112665.001]
  • [Cites] Trends Mol Med. 2005 Jan;11(1):17-22 [15649818.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):5947-51 [12511557.001]
  • [Cites] Mol Cancer Ther. 2005 Nov;4(11):1681-8 [16275989.001]
  • [Cites] Am J Hum Genet. 2001 Sep;69(3):493-503 [11468687.001]
  • [Cites] Am J Pathol. 2005 Jul;167(1):107-16 [15972957.001]
  • [Cites] Curr Neurovasc Res. 2005 Oct;2(4):331-40 [16181124.001]
  • [Cites] Dev Dyn. 2002 May;224(1):18-29 [11984870.001]
  • [Cites] Cell. 1996 Aug 9;86(3):391-9 [8756721.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1639-47 [9403714.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):522-7 [15363802.001]
  • [Cites] Curr Biol. 1996 Oct 1;6(10 ):1302-6 [8939578.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):459-65 [16099633.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7652-6 [14633685.001]
  • [Cites] Biochem Soc Trans. 2003 Jun;31(Pt 3):579-83 [12773159.001]
  • [Cites] Cell Mol Neurobiol. 2005 Aug;25(5):795-805 [16133934.001]
  • [Cites] FEBS Lett. 1999 Sep 17;458(2):247-51 [10481074.001]
  • [Cites] Przegl Lek. 2001;58 Suppl 1:12-5 [11355103.001]
  • [Cites] Arch Pathol Lab Med. 2002 May;126(5):540-4 [11958658.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1411-24 [16211238.001]
  • [Cites] J Biochem. 2002 Nov;132(5):697-703 [12417018.001]
  • [Cites] EMBO J. 1997 Jun 2;16(11):3089-96 [9214626.001]
  • [Cites] J Neurosurg. 2001 Jul;95(1):82-8 [11453402.001]
  • [Cites] Dev Cell. 2003 Mar;4(3):407-18 [12636921.001]
  • [Cites] Hum Mol Genet. 2005 Feb 1;14(3):429-35 [15601645.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):1-5 [16206276.001]
  • [Cites] Nature. 1996 Aug 15;382(6592):638-42 [8757136.001]
  • [Cites] J Biol Chem. 2002 Jun 21;277(25):22175-84 [11943782.001]
  • [Cites] Nature. 1996 Jul 18;382(6588):225-30 [8717036.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5645-50 [12384518.001]
  • [Cites] J Biol Chem. 1997 Nov 14;272(46):29301-8 [9361010.001]
  • (PMID = 16552619.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 0 / Wnt Proteins; 0 / beta Catenin; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein
  • [Number-of-references] 36
  •  go-up   go-down


34. Brown AB, Mahmood U, Cortes ML, Tang Y, Dai G, Stemmer-Rachamimov A, Prabhakar S, Leishear K, Onda H, Kwiatkowski D, Weissleder R, Breakefield X: Magnetic resonance imaging and characterization of spontaneous lesions in a transgenic mouse model of tuberous sclerosis as a model for endothelial cell-based transgene delivery. Hum Gene Ther; 2005 Dec;16(12):1367-76
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberous sclerosis (TSC) is an autosomal dominant genetic disorder characterized by abnormalities in cellular migration, proliferation, and differentiation in many tissues.
  • Benign hamartomas develop in multiple organs, believed to be caused by somatic mutation in addition to germ line mutation to cause loss of both alleles of either the TSC1 or TSC2 tumor suppressor gene, with resultant dysregulated growth due to loss of hamartin or tuberin function, respectively.
  • MRI was shown to be effective in detecting spontaneous lesions in multiple tissues as a means of assessing the prevalence of tumors.
  • [MeSH-major] Gene Transfer Techniques. Genetic Therapy / methods. Tuberous Sclerosis / pathology. Tuberous Sclerosis / therapy. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Animals. Brain / pathology. Cell Line. Disease Models, Animal. Endothelial Cells. Genes, Tumor Suppressor. Green Fluorescent Proteins / genetics. Green Fluorescent Proteins / metabolism. Kidney Neoplasms / pathology. Lung / pathology. Magnetic Resonance Imaging. Mice. Mice, Knockout. Transduction, Genetic. Transgenes

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16390268.001).
  • [ISSN] 1043-0342
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA69246; United States / NINDS NIH HHS / NS / NS24279; United States / NCI NIH HHS / CA / P50 CA86355; United States / NCI NIH HHS / CA / R24 CA92782
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 147336-22-9 / Green Fluorescent Proteins; 4JG2LF96VF / tuberous sclerosis complex 2 protein
  •  go-up   go-down


35. Huang CF, Tu HT, Liu WS, Lin LY: Gamma Knife surgery for trigeminal pain caused by benign brain tumors. J Neurosurg; 2008 Dec;109 Suppl:154-9
MedlinePlus Health Information. consumer health - Trigeminal Neuralgia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma Knife surgery for trigeminal pain caused by benign brain tumors.
  • OBJECT: The authors report the effects of Gamma Knife surgery (GKS) on benign tumor-related trigeminal pain in patients who underwent follow-up for a mean 57.8 months.
  • METHODS: From 1999 to 2004, 21 patients with benign tumor-related trigeminal pain (12 meningiomas and 9 schwannomas) underwent GKS as a primary or repeated treatment.
  • These patients harbored tumors within the radiosurgical target area.
  • For meningiomas, the mean radiosurgical treatment volume was 8.2 ml (range 1.1-21 ml), and the mean radiosurgical tumor margin dose was 12.7 Gy (range 12-15 Gy); for schwannomas, the mean volume was 5.6 ml (range 2-9.2 ml), and the mean marginal dose was 13 Gy (range 11.5-16 Gy).
  • For all 21 patients (100%), control of tumor growth was documented at a mean of 46 months after GKS.
  • CONCLUSIONS: Gamma Knife surgery appears to be an effective tool to treat benign tumor-related trigeminal pain and control tumor growth.
  • [MeSH-major] Brain Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurilemmoma / surgery. Radiosurgery. Trigeminal Neuralgia / prevention & control

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19123903.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Sahu S, Lata I, Gupta D: Management of pregnant female with meningioma for craniotomy. J Neurosci Rural Pract; 2010 Jan;1(1):35-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intracranial meningioma during pregnancy challenges the skill of obstetricians, neurosurgeons and neuroanesthesiologists in resection of the tumor and to secure delivery of the baby.
  • Urgent neurosurgical intervention is reserved for the management of malignancies, active hydrocephalus, and benign brain tumors associated with signs of impending herniation or progressive neurological deficit.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Obstet Gynecol Scand. 2001 Feb;80(2):104-12 [11167203.001]
  • [Cites] Am J Obstet Gynecol. 2002 Sep;187(3):626-34 [12237639.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2004 Jun;286(6):H2127-32 [14751854.001]
  • [Cites] Arch Neurol. 1987 Feb;44(2):209-15 [3545159.001]
  • [Cites] J Neurosurg. 1991 Nov;75(5):731-9 [1919695.001]
  • [Cites] Am J Obstet Gynecol. 1994 Oct;171(4):1128-32 [7943085.001]
  • [Cites] J Reprod Med. 1995 Feb;40(2):154-6 [7738930.001]
  • [Cites] Can J Anaesth. 1999 Jan;46(1):61-5 [10078406.001]
  • [Cites] Clin Pharmacokinet. 2005;44(10):989-1008 [16176115.001]
  • [Cites] Pediatrics. 2006 May;117(5):1503-10 [16651303.001]
  • [Cites] Curr Opin Anaesthesiol. 2006 Oct;19(5):481-6 [16960478.001]
  • [Cites] Hypertension. 2007 Feb;49(2):334-40 [17200432.001]
  • [Cites] Anesth Analg. 2008 Jul;107(1):193-200 [18635488.001]
  • [Cites] J Neurosurg. 2009 Dec;111(6):1150-7 [19408979.001]
  • (PMID = 21799618.001).
  • [ISSN] 0976-3155
  • [Journal-full-title] Journal of neurosciences in rural practice
  • [ISO-abbreviation] J Neurosci Rural Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3137832
  • [Keywords] NOTNLM ; Craniotomy / complications / meningioma / pregnancy
  •  go-up   go-down


37. Badr El-Din NK, Settin A, Ali N, Abdel-Hady el-SK, Salem FK: Cytokine gene polymorphisms in egyptian cases with brain tumors. J Egypt Natl Canc Inst; 2009 Jun;21(2):101-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine gene polymorphisms in egyptian cases with brain tumors.
  • BACKGROUND: Cytokines are proposed to play important roles in brain tumor biology as well as neurodegeneration or impaired neuronal function.
  • OBJECTIVES: This work aimed to check the association of polymorphisms of cytokine genes in Egyptian cases with brain tumors.
  • METHODS: This work included 45 cases affected by brain tumors diagnosed as 24 benign and 21 malignant.
  • RESULTS: Cases affected with benign brain tumors showed a significant higher frequency of IL-10-1082 A/A [odds ratio (OR=8.0), p<0.001] and IL-6-174 C/C (OR=6.3, p=0.002) homozygous genotypes as compared to controls.
  • CONCLUSIONS: Cytokine gene polymorphisms showed a pattern of association with brain tumors which may have potential impact on family counseling and disease management.
  • [MeSH-major] Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Cytokines / genetics. Polymorphism, Genetic / genetics
  • [MeSH-minor] Case-Control Studies. DNA / genetics. Egypt. Female. Genotype. Humans. Interleukin 1 Receptor Antagonist Protein / genetics. Interleukin-10 / genetics. Interleukin-6 / genetics. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Tumor Necrosis Factor-alpha / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21057561.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / Interleukin 1 Receptor Antagonist Protein; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 9007-49-2 / DNA
  •  go-up   go-down


38. Nakase Y, Fukuda K, Chikashige Y, Tsutsumi C, Morita D, Kawamoto S, Ohnuki M, Hiraoka Y, Matsumoto T: A defect in protein farnesylation suppresses a loss of Schizosaccharomyces pombe tsc2+, a homolog of the human gene predisposing to tuberous sclerosis complex. Genetics; 2006 Jun;173(2):569-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations in the human Tsc1 and Tsc2 genes predispose to tuberous sclerosis complex (TSC), a disorder characterized by the wide spread of benign tumors.
  • [MeSH-major] Genes, Fungal. Schizosaccharomyces / genetics. Schizosaccharomyces / metabolism. Schizosaccharomyces pombe Proteins / genetics. Schizosaccharomyces pombe Proteins / metabolism. Tuberous Sclerosis / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • Hazardous Substances Data Bank. Nitrogen, Elemental .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genetics. 2000 Jun;155(2):611-22 [10835385.001]
  • [Cites] Mol Microbiol. 2005 Nov;58(4):1074-86 [16262791.001]
  • [Cites] Mol Microbiol. 2001 Sep;41(6):1339-47 [11580838.001]
  • [Cites] Hum Mol Genet. 2002 Mar 1;11(5):525-34 [11875047.001]
  • [Cites] Genetics. 2002 Jul;161(3):1053-63 [12136010.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):629-35 [12509460.001]
  • [Cites] Mol Biol Cell. 2003 Mar;14(3):1109-24 [12631727.001]
  • [Cites] Nat Cell Biol. 2003 Jun;5(6):578-81 [12771962.001]
  • [Cites] Mol Cell. 2003 Jun;11(6):1467-78 [12820961.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Dec;38(4):368-75 [14566857.001]
  • [Cites] Trends Biochem Sci. 2003 Nov;28(11):573-6 [14607085.001]
  • [Cites] Trends Biochem Sci. 2004 Jan;29(1):32-8 [14729330.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12706-13 [14718525.001]
  • [Cites] Trends Cell Biol. 2004 Feb;14(2):78-85 [15102439.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(18):7965-75 [15340059.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1980 Feb;49(2):166-70 [6766544.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 May;80(10):3035-9 [6344075.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Nov;86(21):8323-7 [2682646.001]
  • [Cites] Nucleic Acids Res. 1990 Nov 25;18(22):6485-9 [2251111.001]
  • [Cites] Methods Enzymol. 1991;194:795-823 [2005825.001]
  • [Cites] Mol Biol Cell. 1995 Sep;6(9):1185-95 [8534915.001]
  • [Cites] Annu Rev Immunol. 1996;14:483-510 [8717522.001]
  • [Cites] Am J Hum Genet. 1996 Aug;59(2):400-6 [8755927.001]
  • [Cites] Brain Dev. 1995;17 Suppl:55-7 [8882573.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1800-4 [9065406.001]
  • [Cites] J Biol Chem. 1997 Jul 11;272(28):17776-83 [9211930.001]
  • [Cites] Science. 1997 Aug 8;277(5327):805-8 [9242607.001]
  • [Cites] Trends Pharmacol Sci. 1997 Nov;18(11):437-44 [9426472.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Apr 7;245(1):246-53 [9535817.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5239-46 [9710608.001]
  • [Cites] Mol Microbiol. 1998 Sep;29(6):1357-67 [9781874.001]
  • [Cites] Biochemistry. 1998 Nov 24;37(47):16601-11 [9843427.001]
  • [Cites] Cell. 1999 Feb 19;96(4):529-39 [10052455.001]
  • [Cites] Cancer Treat Rev. 2004 Nov;30(7):609-41 [15531395.001]
  • [Cites] Mutat Res. 2001 Jul;488(3):233-9 [11397651.001]
  • [Cites] Nucleic Acids Res. 1992 Mar 25;20(6):1425 [1561104.001]
  • [Cites] Gene. 1993 Jan 15;123(1):127-30 [8422996.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1305-15 [8269512.001]
  • [Cites] Genes Dev. 1994 Feb 1;8(3):328-38 [8314086.001]
  • [Cites] Arch Dermatol. 1994 Mar;130(3):348-54 [8129414.001]
  • [Cites] Nature. 1999 Dec 9;402(6762):689-92 [10604478.001]
  • [Cites] J Biol Chem. 2000 Jan 7;275(1):429-38 [10617635.001]
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):11198-206 [10753927.001]
  • [Cites] Mol Cell Biol. 2000 May;20(10):3459-69 [10779336.001]
  • [Cites] Genes Dev. 1991 Nov;5(11):1990-9 [1657709.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):193-6 [8162074.001]
  • [Cites] Gene. 1994 Apr 8;141(1):133-6 [8163165.001]
  • [Cites] Hum Mol Genet. 1994 Oct;3(10):1829-32 [7849708.001]
  • [Cites] Hum Mol Genet. 1994 Oct;3(10):1833-4 [7849709.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):297-300 [15837619.001]
  • [Cites] Curr Biol. 2005 Apr 26;15(8):702-13 [15854902.001]
  • [Cites] Hum Mol Genet. 2005 Oct 1;14(19):2851-8 [16115814.001]
  • [ErratumIn] Genetics. 2006 Aug;173(4):2419
  • (PMID = 16624901.001).
  • [ISSN] 0016-6731
  • [Journal-full-title] Genetics
  • [ISO-abbreviation] Genetics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Fungal; 0 / Schizosaccharomyces pombe Proteins; 0 / Tsc1 protein, S pombe; 0 / Tsc2 protein, S pombe; 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein; EC 2.5.1.29 / Farnesyltranstransferase; EC 3.6.1.- / GTP Phosphohydrolases; EC 3.6.1.- / Rhb1 protein, S pombe; N762921K75 / Nitrogen
  • [Other-IDs] NLM/ PMC1526497
  •  go-up   go-down


39. Utermark T, Kaempchen K, Antoniadis G, Hanemann CO: Reduced apoptosis rates in human schwannomas. Brain Pathol; 2005 Jan;15(1):17-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Schwannomas, tumors originating from Schwann cells, represent a frequent neurological tumor and can occur both in a genetic disorder called neurofibromatosis type 2 (NF2) and sporadically.
  • In both cases the genetic background is identical as all schwannomas are caused by biallelic mutations in the tumor suppressor gene NF2 coding for merlin.
  • Here, we report in vivo and in vitro evidence that the basal apoptosis rate of primary human schwannoma cells is reduced in comparison to that of normal Schwann cells, supporting the idea that in this benign tumor type, apoptosis has a role in tumorigenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15779232.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


40. Hohenstein C, Herdtle S: Unexpected death from a colloid cyst. Int J Emerg Med; 2010;3(1):65-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Colloid cysts are usually benign brain tumors, which rarely cause acute neurological deterioration with sudden death due to an acute increase of intracranial pressure.
  • CONCLUSION: Subtle distinctions between symptoms due to intracranial hypertension, which typically cause headache and vomiting, and true gastroenteritis are discussed as well as the pathophysiology of neurogenic pulmonary edema and the origin of cerebral-triggered cardiac dysrhythmias.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1996 Feb;38(2):392-5 [8869070.001]
  • [Cites] Ann Emerg Med. 1997 Apr;29(4):524-8 [9095015.001]
  • [Cites] Clin Neurol Neurosurg. 2002 Sep;104(4):367-70 [12140107.001]
  • [Cites] Childs Nerv Syst. 2006 Mar;22(3):305-9 [16180045.001]
  • [Cites] J Clin Neurosci. 1995 Oct;2(4):307-11 [18638833.001]
  • [Cites] Acta Anaesthesiol Scand. 2007 Apr;51(4):447-55 [17378783.001]
  • [Cites] Physiol Res. 2008;57(4):499-506 [18052674.001]
  • [Cites] Am J Forensic Med Pathol. 2008 Jun;29(2):170-2 [18520488.001]
  • [Cites] Pediatr Cardiol. 2006 Mar-Apr;27(2):286-8 [16463127.001]
  • (PMID = 20414387.001).
  • [ISSN] 1865-1380
  • [Journal-full-title] International journal of emergency medicine
  • [ISO-abbreviation] Int J Emerg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2850975
  • [Keywords] NOTNLM ; Cardiopulmonary complication / Colloid cyst / Unexpected death
  •  go-up   go-down


41. Liu J, Zheng S, Yu JK, Yu XB, Liu WG, Zhang JM, Hu X: [Establishment of diagnostic model of cerebrospinal protein fingerprint pattern for glioma and its clinical application]. Zhejiang Da Xue Xue Bao Yi Xue Ban; 2005 Mar;34(2):141-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Seventy-five samples of cerebrospinal fluid from patients with gliomas, benign brain tumors and mild brain traumas were collected.
  • A total of 50 samples from gliomas and non-brain-tumors were divided into training sets (33 cases including 17 gliomas and 16 non-brain-tumors) and testing sets (17 cases including 5 gliomas and 12 non-brain-tumors).
  • The cerebrospinal proteins bound to H4 chip were detected by SELDI-TOF MS, the profiles of cerebrospinal protein were gained and then analyzed with artificial neural network algorithm (ANN); and the diagnostic model of cerebrospinal protein profiles for differentiating gliomas from non-brain-tumors was established.
  • Forty-seven of cerebrospinal samples of gliomas and benign brain tumors were divided into training sets (31 cases including 13 gliomas and 18 benign brain tumors) and testing sets (16 cases including 9 gliomas and 7 benign brain tumors), the diagnostic model of cerebrospinal protein profiles for differentiating gliomas from benign brain tumors was established based on the same method.
  • RESULT: The diagnostic model of cerebrospinal protein profiles for differentiating gliomas from non-brain-tumors was established and was challenged with the test set randomly, the sensitivity and specificity were 100% and 91.7%, respectively.
  • The cerebrospinal protein profiling model for differentiating gliomas from benign brain tumors was also developed and was challenged with the test set randomly, the sensitivity and specificity were 88.9%, and 100%, respectively.
  • CONCLUSION: The technology of SELDI-TOF MS which combined with analysis tools of bioinformatics is a novel effective method for screening and identifying tumor biomarkers of gliomas and it may provide a new approach for the clinical diagnosis of glioma.
  • [MeSH-major] Brain Neoplasms / cerebrospinal fluid. Cerebrospinal Fluid Proteins / genetics. Glioma / cerebrospinal fluid. Peptide Mapping / standards
  • [MeSH-minor] Adult. Aged. Algorithms. Biomarkers, Tumor. Diagnosis, Differential. Female. Humans. Male. Meningioma / cerebrospinal fluid. Meningioma / diagnosis. Middle Aged. Neural Networks (Computer). Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15812888.001).
  • [ISSN] 1008-9292
  • [Journal-full-title] Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  • [ISO-abbreviation] Zhejiang Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cerebrospinal Fluid Proteins
  •  go-up   go-down


42. Chou CH, Lieu AS, Wu CH, Chang LK, Loh JK, Lin RC, Chen WJ, Liao HD, Fu WS, Chang CS, Lin CC, Hsu CM, Chio CC, Howng SL, Hong YR: Differential expression of hedgehog signaling components and Snail/E-cadherin in human brain tumors. Oncol Rep; 2010 Nov;24(5):1225-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of hedgehog signaling components and Snail/E-cadherin in human brain tumors.
  • However, the role of Hh signaling components and Snail/E-cadherin in brain tumors is not yet fully understood.
  • We analyzed the expression of Hh signaling components and Snail/E-cadherin in 69 brain tumors by reverse transcription-polymerase chain reaction (RT-PCR).
  • The data showed that overexpression of Smo (35/69), Ptch (50/69), Gli1 (56/69), Gli2 (29/69) and N-myc (39/69) might contribute to brain tumorigenesis.
  • Our results also indicated that Snail and E-cadherin showed opposing expression in malignant tumors (high grade astrocytoma and metastasis).
  • Snail and E-cadherin showed less correlation in benign brain tumors.
  • Taken together, our results demonstrate that Hh signaling components, the expression and mutations of Snail and the expression of E-cadherin may play an important role in human brain tumorigenesis.
  • [MeSH-major] Brain Neoplasms / genetics. Cadherins / genetics. Hedgehog Proteins / genetics. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20878114.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cadherins; 0 / Hedgehog Proteins; 0 / Transcription Factors; 0 / snail family transcription factors
  •  go-up   go-down


43. Kernick D, Stapley S, Goadsby PJ, Hamilton W: What happens to new-onset headache presented to primary care? A case-cohort study using electronic primary care records. Cephalalgia; 2008 Nov;28(11):1188-95
MedlinePlus Health Information. consumer health - Headache.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Records of patients who presented with primary headache (migraine, tension-type headache, cluster headache) or undifferentiated headache (no further descriptor) were examined for the subsequent year for subarachnoid haemorrhage, primary brain tumour, benign space-occupying lesion, temporal arteritis, stroke and transient ischaemic attack.
  • The 1-year risk of a malignant brain tumour with new undifferentiated headache was 0.15%, rising to 0.28% above the age of 50 years.
  • The risk for a benign space-occupying lesion was 0.05% for an undifferentiated and 0.009% for a primary headache.
  • Accepting the limitations of this approach, our data can inform management guidelines for new presentations of headache in primary care and confirm the need for follow-up, even if a primary headache diagnosis is made.
  • [MeSH-major] Headache / diagnosis. Headache / epidemiology. Headache / etiology
  • [MeSH-minor] Adult. Brain Diseases / complications. Case-Control Studies. Female. Humans. Male. Middle Aged. Primary Health Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Headache. 2011 Feb;51(2):346-52 [21284622.001]
  • (PMID = 18771496.001).
  • [ISSN] 1468-2982
  • [Journal-full-title] Cephalalgia : an international journal of headache
  • [ISO-abbreviation] Cephalalgia
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


44. Khong SY, Leach J, Greenwood C: Meningioma mimicking puerperal psychosis. Obstet Gynecol; 2007 Feb;109(2 Pt2):515-6
MedlinePlus Health Information. consumer health - Psychotic Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Meningiomas are slow-growing benign brain tumors.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Psychotic Disorders / etiology. Puerperal Disorders / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Pregnancy. Pregnancy Trimester, Third

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Postpartum Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17267878.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Jozwiak J, Kotulska K, Grajkowska W, Jozwiak S, Zalewski W, Oldak M, Lojek M, Rainko K, Maksym R, Lazarczyk M, Skopinski P, Wlodarski P: Upregulation of the WNT pathway in tuberous sclerosis-associated subependymal giant cell astrocytomas. Brain Dev; 2007 Jun;29(5):273-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberous sclerosis (TS), autosomal dominant disorder manifested by the formation of usually benign tumors in the brain, heart, kidneys and skin, results from an inactivating mutation in one of two tumor suppressor genes TSC1 or TSC2.
  • In order to test this hypothesis we evaluated samples of four subependymal giant cell astrocytomas (SEGAs), brain tumors developing in the progress of TS.
  • [MeSH-major] Astrocytoma / complications. Astrocytoma / physiopathology. Brain Neoplasms / complications. Brain Neoplasms / physiopathology. Signal Transduction / physiology. Tuberous Sclerosis / etiology. Tuberous Sclerosis / physiopathology. Up-Regulation / physiology. Wnt Proteins / physiology


46. De Marinis L, Fusco A, Bianchi A, Aimaretti G, Ambrosio MR, Scaroni C, Cannavo S, Di Somma C, Mantero F, degli Uberti EC, Giordano G, Ghigo E: Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: preliminary report. J Endocrinol Invest; 2006 Jun;29(6):516-22
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: preliminary report.
  • It may occur after neurosurgical treatment of brain tumors arising near sella turcica.
  • The aim of this study was to evaluate pituitary function in particular GH deficiency (GHD) in patients submitted to neurosurgery for benign tumors of the central nervous system (CNS) not involving hypothalamic-pituitary region.
  • We observed 37 patients with benign brain tumors [13 males, 24 females, age: 54.6+/-13.9 yr; body mass index (BMI): 25.1+/-4.0 kg/m2] performing a basic evaluation of the pituitary function and a dynamic test of the GH/IGF-I axis [GHRH (1 microg/kg iv)+arginine (0.5 g/kg iv) test] for 3 and 12 months after the neurosurgical treatment.
  • This data suggests that hypopituitarism of various degree may develop in patients who are submitted to neurosurgery for primary brain tumors, even far from hypothalamic-pituitary region.
  • [MeSH-major] Brain Neoplasms / surgery. Hypopituitarism / etiology. Postoperative Complications

  • Genetic Alliance. consumer health - Hypopituitarism.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1998 Jul 11;352(9122):127-34 [9672293.001]
  • [Cites] Endocrine. 2001 Jun;15(1):29-38 [11572322.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Dec;90(12):6355-60 [16144946.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Sep;61(3):320-6 [15355447.001]
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1615-8 [9589665.001]
  • [Cites] J Endocrinol Invest. 2004 Dec;27(11):1048-54 [15754737.001]
  • [Cites] Horm Res. 2004;62 Suppl 1:26-33 [15761229.001]
  • [Cites] J Cereb Blood Flow Metab. 1998 Aug;18(8):833-9 [9701344.001]
  • [Cites] Horm Res. 2003;59 Suppl 1:1-11 [12566714.001]
  • [Cites] Neuropathol Appl Neurobiol. 1997 Aug;23(4):307-14 [9292869.001]
  • [Cites] Expert Opin Pharmacother. 2004 May;5(5):1023-31 [15155105.001]
  • [Cites] Neurologist. 2004 May;10(3):113-30 [15140272.001]
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):662-9 [10603007.001]
  • [Cites] Growth Horm IGF Res. 2004 Jun;14 Suppl A:S118-24 [15135792.001]
  • [Cites] Neurosurg Clin N Am. 2003 Oct;14(4):571-91 [15024802.001]
  • [Cites] Growth Horm IGF Res. 2004 Jun;14 Suppl A:S114-7 [15135791.001]
  • [Cites] Eur J Pediatr. 1997 Oct;156(10):764-9 [9365064.001]
  • [Cites] Curr Opin Neurol. 2002 Dec;15(6):663-9 [12447103.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):499-509 [15509483.001]
  • [Cites] J Neurosci. 2000 Nov 1;20(21):7994-8004 [11050120.001]
  • [Cites] J Invest Surg. 2004 Sep-Oct;17(5):283-9 [15385261.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):477-85 [11836272.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):495-506 [12057095.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):377-84 [15015671.001]
  • (PMID = 16840829.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Somatomedins; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; 9002-71-5 / Thyrotropin; 9002-72-6 / Growth Hormone; 9034-39-3 / Growth Hormone-Releasing Hormone; 94ZLA3W45F / Arginine; Q51BO43MG4 / Thyroxine; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


47. Debling D, Spix C, Blettner M, Michaelis J, Kaatsch P: The cohort of long-term survivors at the German childhood cancer registry. Klin Padiatr; 2008 Nov-Dec;220(6):371-7
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Since 1980 the GCCR systematically ascertains all malignant neoplasms and benign brain tumours in children under the age of 15 years at diagnosis.
  • Participants are followed up actively by the treating hospitals and the clinical study groups in the first years after diagnosis, and by the GCCR thereafter.
  • Those groups are the GCCR (secondary malignant neoplasms), LESS (late effects after chemotherapy), RiSK (late effects after radiotherapy), and the working group on quality of life (quality of life and data on life circumstances).
  • LTS for patients with leukemia and lymphomas is particularly complete, whereas for patients with brain tumours it is less complete.
  • [MeSH-major] Brain Neoplasms / therapy. Leukemia / therapy. Lymphoma / therapy. Neoplasms / therapy. Registries. Survivors
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cohort Studies. Follow-Up Studies. Humans. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / therapy. Young Adult


48. Liu AK, Bagrosky B, Fenton LZ, Gaspar LE, Handler MH, McNatt SA, Foreman NK: Vascular abnormalities in pediatric craniopharyngioma patients treated with radiation therapy. Pediatr Blood Cancer; 2009 Feb;52(2):227-30
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Craniopharyngioma is a benign brain tumor that can be treated with some combination of surgery, intracystic chemotherapy and radiation therapy.
  • One had bilateral temporal cavernomas, one had moyamoya syndrome, one had an aneurysm of the internal carotid artery and three children had decreases in the caliber of the carotid or cerebral arteries, but were asymptomatic.

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Vascular Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18937328.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin
  •  go-up   go-down


49. Landau D, Avgeropoulos N, Ma J: Cerebral amyloidoma mimicking intracranial tumor: a case report. J Med Case Rep; 2010;4:308

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral amyloidoma mimicking intracranial tumor: a case report.
  • INTRODUCTION: Cerebral amyloidoma is an infrequently recognized condition that can be confused with a more malignant etiology.
  • CASE PRESENTATION: Our patient was a 64-year-old Caucasian man who was incidentally discovered to have a brain mass.
  • He was found to have a cerebral amyloidoma.
  • CONCLUSION: After discovery of the true etiology of his brain abnormality, it was determined that our patient had a more benign disease than was initially feared.
  • Cases such as this demonstrate why consideration of this disorder is important.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20854655.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2946306
  •  go-up   go-down


50. Albers AC, Gutmann DH: Gliomas in patients with neurofibromatosis type 1. Expert Rev Neurother; 2009 Apr;9(4):535-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis type 1 (NF1) is an inherited autosomal dominant disorder characterized by numerous cutaneous features, including café-au-lait macules, skinfold freckling and iris hamartomas.
  • In addition, individuals with NF1 are prone to the development of both benign and malignant tumors.
  • The most common CNS tumor in children and adults with NF1 is the glioma.
  • Regular ophthalmologic evaluations in children are essential for the effective management of these tumors in patients with NF1.
  • [MeSH-major] Brain Neoplasms / complications. Glioma / complications. Neurofibromatosis 1 / complications


51. Mizuguchi M: Abnormal giant cells in the cerebral lesions of tuberous sclerosis complex. Congenit Anom (Kyoto); 2007 Mar;47(1):2-8
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal giant cells in the cerebral lesions of tuberous sclerosis complex.
  • Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations of either of the two tumor suppressor genes, TSC1 and TSC2, encoding hamartin and tuberin, respectively.
  • TSC is pathologically characterized by the occurrence of multiple hamartias (focal dysplasias) and hamartomas (benign tumors) in the brain and many other organs.
  • Cortical tubers are hamartias in the cerebral cortex responsible for many neuropsychiatric symptoms of TSC.
  • [MeSH-major] Cerebral Cortex / pathology. Giant Cells / pathology. Tuberous Sclerosis / pathology
  • [MeSH-minor] Animals. Cell Differentiation. Cell Size. Genes, Tumor Suppressor. Hamartoma / pathology. Humans. Models, Animal. Models, Biological

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17300684.001).
  • [ISSN] 0914-3505
  • [Journal-full-title] Congenital anomalies
  • [ISO-abbreviation] Congenit Anom (Kyoto)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Number-of-references] 67
  •  go-up   go-down


52. Niranjan A, Kondziolka D, Lunsford LD: Neoplastic transformation after radiosurgery or radiotherapy: risk and realities. Otolaryngol Clin North Am; 2009 Aug;42(4):717-29
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In recent years, the use of radiosurgery or radiotherapy for benign brain tumors has increased significantly.
  • Although long-term follow-up from several centers suggests that radiosurgery or radiotherapy is effective and safe, there are particular concerns regarding development of radiation-induced tumors.
  • This article reviews the use of radiosurgery and fractionated radiation therapy with particular regard to new tumor induction and malignant transformation.
  • The authors have found that the risk of radiation associated tumors after radiosurgery or radiotherapy for benign brain tumors is very low.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Cell Transformation, Neoplastic / pathology. Neoplasms, Radiation-Induced / epidemiology. Neoplasms, Radiation-Induced / pathology. Radiosurgery / adverse effects

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19751875.001).
  • [ISSN] 1557-8259
  • [Journal-full-title] Otolaryngologic clinics of North America
  • [ISO-abbreviation] Otolaryngol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


53. Matsuo Y, Kamitani T: Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma. PLoS One; 2010;5(5):e10481
MedlinePlus Health Information. consumer health - Parkinson's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parkinson's disease is a neurodegenerative disorder that is caused by mutation of alpha-synuclein or other genes.
  • CONCLUSIONS/SIGNIFICANCE: The Parkinson's disease-related protein, alpha-synuclein, is expressed in both malignant and benign melanocytic lesions, such as melanomas and nevi.
  • Although alpha-synuclein cannot be used to distinguish between malignant and benign melanocytic skin lesions, it might be a useful biomarker for the diagnosis of metastatic melanoma.
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Cell Line, Tumor. Female. Humans. MART-1 Antigen. Male. Melanins / metabolism. Middle Aged. Neoplasm Proteins / metabolism. Nevus / metabolism. Nevus / pathology. Pigmentation. Retinoblastoma / metabolism. Retinoblastoma / pathology. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2001 Mar;54(3):196-200 [11253130.001]
  • [Cites] Neurology. 2009 Oct 20;73(16):1286-91 [19841380.001]
  • [Cites] J Neurosci. 2002 Apr 15;22(8):3090-9 [11943812.001]
  • [Cites] Nat Rev Neurosci. 2002 Jul;3(7):531-41 [12094209.001]
  • [Cites] Traffic. 2002 Sep;3(9):678-93 [12191019.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):217-23 [14991540.001]
  • [Cites] J Immunother. 1998 Jan;21(1):27-31 [9456433.001]
  • [Cites] Cancer. 1999 Feb 25;87(1):37-42 [10096358.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):617-27 [10440689.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):201-5 [15583688.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):687-701 [15721476.001]
  • [Cites] J Cell Sci. 2005 Aug 1;118(Pt 15):3523-30 [16030137.001]
  • [Cites] Epidemiology. 2006 Sep;17(5):582-7 [16837822.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Oct;8(10):786-97 [17878918.001]
  • [Cites] Orphanet J Rare Dis. 2007;2:43 [17980020.001]
  • [Cites] Nat Clin Pract Oncol. 2009 Feb;6(2):105-17 [19107110.001]
  • [Cites] Virchows Arch. 2009 May;454(5):505-11 [19352698.001]
  • [Cites] Biochim Biophys Acta. 2009 Jul;1792(7):616-24 [18955133.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1039-46 [11474288.001]
  • (PMID = 20463956.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / R01 AG024497
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanins; 0 / Neoplasm Proteins; 0 / alpha-Synuclein
  • [Other-IDs] NLM/ PMC2864738
  •  go-up   go-down


54. Carlson ML, Babovic-Vuksanovic D, Messiaen L, Scheithauer BW, Neff BA, Link MJ: Radiation-induced rhabdomyosarcoma of the brainstem in a patient with neurofibromatosis type 2. J Neurosurg; 2010 Jan;112(1):81-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis Type 2 (NF2) is a rare autosomal dominant disorder characterized by the development of benign tumors of the peripheral nervous system and the CNS, including schwannomas, meningiomas, and ependymomas.
  • The gene responsible for the development of NF2 acts as a tumor suppressor gene.
  • Stereotactic radiotherapy (SRT) or single-fraction stereotactic radiosurgery has been increasingly used in the past decades to treat benign tumors in patients with NF2.
  • These radiotherapy methods are less invasive and can be potentially used to treat multiple tumors in a single session.
  • Few reports exist of malignant peripheral nerve sheath tumors, meningiomas, or ependymomas occurring after SRT or stereotactic radiosurgery in patients with NF2.
  • Compared with patients with sporadic tumors, NF2 patients having a germline tumor suppressor gene defect may be more prone to secondary malignancies after treatment involving radiation therapy.
  • [MeSH-major] Brain Stem Neoplasms / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Neurofibromatosis 2 / surgery. Radiosurgery / adverse effects. Rhabdomyosarcoma / etiology
  • [MeSH-minor] Adult. Brain Neoplasms / etiology. Brain Neoplasms / surgery. Brain Stem / pathology. Brain Stem / radiation effects. Brain Stem / surgery. Ear Neoplasms / etiology. Ear Neoplasms / surgery. Fatal Outcome. Female. Humans. Neurilemmoma / etiology. Neurilemmoma / surgery. Vestibular Diseases / etiology. Vestibular Diseases / surgery

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurosurg. 2010 Jan;112(1):209. Scheithauer, Bernd B [corrected to Scheithauer, Bernd W]
  • (PMID = 19575577.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Georgiadis P, Cavouras D, Kalatzis I, Glotsos D, Athanasiadis E, Kostopoulos S, Sifaki K, Malamas M, Nikiforidis G, Solomou E: Enhancing the discrimination accuracy between metastases, gliomas and meningiomas on brain MRI by volumetric textural features and ensemble pattern recognition methods. Magn Reson Imaging; 2009 Jan;27(1):120-30
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancing the discrimination accuracy between metastases, gliomas and meningiomas on brain MRI by volumetric textural features and ensemble pattern recognition methods.
  • Three-dimensional (3D) texture analysis of volumetric brain magnetic resonance (MR) images has been identified as an important indicator for discriminating among different brain pathologies.
  • The purpose of this study was to evaluate the efficiency of 3D textural features using a pattern recognition system in the task of discriminating benign, malignant and metastatic brain tissues on T1 postcontrast MR imaging (MRI) series.
  • The dataset consisted of 67 brain MRI series obtained from patients with verified and untreated intracranial tumors.
  • The latter, in conjunction with using 3D textural features, enabled boosting up the performance of the system in discriminating metastatic, malignant and benign brain tumors with 77.14%, 89.19% and 93.33% accuracy, respectively.
  • The proposed system might be used as an assisting tool for brain tumor characterization on volumetric MRI series.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioma / diagnosis. Image Enhancement / methods. Imaging, Three-Dimensional. Magnetic Resonance Imaging / methods. Meningioma / diagnosis. Pattern Recognition, Automated / methods
  • [MeSH-minor] Diagnosis, Differential. Humans. Least-Squares Analysis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602785.001).
  • [ISSN] 0730-725X
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


56. Boviatsis EJ, Bouras TI, Kouyialis AT, Themistocleous MS, Sakas DE: Impact of age on complications and outcome in meningioma surgery. Surg Neurol; 2007 Oct;68(4):407-11; discussion 411
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Surgery for benign brain tumors in elderly patients without severe general health problems is an acceptable practice, as results are comparable with the ones of younger patients.
  • Tumor removal rate was not significantly different in the 2 groups.
  • Regarding each complication, postoperative hematoma, infections, and deep vein thrombosis were more frequent in elderly patients, presenting various degrees of statistical significance, whereas postoperative brain edema, hydrocephalus, and cardiorespiratory incidents presented no statistically significant difference.
  • [MeSH-major] Meningioma / surgery. Postoperative Complications / epidemiology. Supratentorial Neoplasms / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cerebral Hemorrhage / etiology. Craniotomy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Nervous System Diseases / epidemiology. Neurosurgical Procedures. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17586023.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Sadetzki S, Chetrit A, Freedman L, Stovall M, Modan B, Novikov I: Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis. Radiat Res; 2005 Apr;163(4):424-32
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis.
  • Ionizing radiation is an established risk factor for brain tumors, yet quantitative information on the long-term risk of different types of brain tumors is sparse.
  • Our aims were to assess the risk of radiation-induced malignant brain tumors and benign meningiomas after childhood exposure and to investigate the role of potential modifiers of that risk.
  • The mean estimated radiation dose to the brain was 1.5 Gy.
  • Survival analysis using Poisson regression was performed to estimate the excess relative and absolute risks (ERR, EAR) for brain tumors.
  • After a median follow-up of 40 years, an ERR/Gy of 4.63 and 1.98 (95% CI = 2.43-9.12 and 0.73-4.69) and an EAR/Gy per 10(4) PY of 0.48 and 0.31 (95% CI = 0.28-0.73 and 0.12-0.53) were observed for benign meningiomas and malignant brain tumors, respectively.
  • The risk of both types of tumors was positively associated with dose.
  • The estimated ERR/Gy for malignant brain tumors decreased with increasing age at irradiation from 3.56 to 0.47 (P = 0.037), while no trend with age was seen for benign meningiomas.
  • The ERR for both types of tumor remains elevated at 30-plus years after exposure.
  • [MeSH-major] Brain / radiation effects. Brain Neoplasms / epidemiology. Neoplasms, Radiation-Induced / epidemiology. Radiotherapy / statistics & numerical data. Risk Assessment / methods. Tinea Capitis / epidemiology. Tinea Capitis / radiotherapy


58. Prabhu SS, Bruner JM: Large oculomotor schwannoma presenting as a parasellar mass: A case report and literature review. Surg Neurol Int; 2010;1:15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The common site of tumor occurrence in this nerve is the segment within the interpeduncular cistern and the cavernous sinus.
  • The radiological features of the mass were more consistent with a medial sphenoid wing meningioma causing brain stem compression.
  • Complete resection of the tumor was achieved via a left pterional approach.
  • CONCLUSION: The management of these large benign tumors with brain stem compression includes surgical resection.
  • Intraoperative anatomical preservation of the third nerve was impossible given its course in the tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1992 Sep;38(3):216-24 [1440207.001]
  • [Cites] Neurochirurgie. 1992;38(3):183-7 [1461338.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Feb;30(2):132-6 [1695335.001]
  • [Cites] Clin Neurol Neurosurg. 1990;92(4):333-5 [1963824.001]
  • [Cites] Br J Neurosurg. 1990;4(1):69-72 [2185790.001]
  • [Cites] Surg Neurol. 1985 Sep;24(3):275-8 [4023908.001]
  • [Cites] Surg Neurol. 2007 Jan;67(1):83-8; discussion 88 [17210311.001]
  • [Cites] J Neurosurg. 1982 Jun;56(6):854-6 [7077388.001]
  • [Cites] J Neurosurg. 1982 Oct;57(4):563-5 [7108608.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(11):1147-51 [9870060.001]
  • [Cites] Br J Neurosurg. 2003 Apr;17(2):168-73 [12820761.001]
  • [Cites] Skull Base Surg. 1994;4(4):219-26 [17171175.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1981 May;44(5):397-401 [7021770.001]
  • (PMID = 20657696.001).
  • [ISSN] 2152-7806
  • [Journal-full-title] Surgical neurology international
  • [ISO-abbreviation] Surg Neurol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2908360
  • [Keywords] NOTNLM ; Meningioma / oculomotor schwannoma / skull base
  •  go-up   go-down


59. Mainio A, Tuunanen S, Hakko H, Niemelä A, Koivukangas J, Räsänen P: Decreased quality of life and depression as predictors for shorter survival among patients with low-grade gliomas: a follow-up from 1990 to 2003. Eur Arch Psychiatry Clin Neurosci; 2006 Dec;256(8):516-21
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To assess the long-term survival of brain tumor patients, and in particular to evaluate the relation of quality of life (QOL) to survival among low-grade glioma patients.
  • METHODS: The postoperative survival of 101 brain tumor patients was followed from surgery (1990-1992) until the end of the year 2003.
  • RESULTS: The mean survival times in years (SD) were significantly related to tumor malignancy, being the shortest, 1.9 (0.6), for patients with high-grade gliomas, while patients with low-grade gliomas or a benign brain tumor had mean survival times of 9.1 (1.0) and 11.6 (0.5), respectively.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / psychology. Depressive Disorder / mortality. Depressive Disorder / psychology. Glioma / mortality. Glioma / psychology. Quality of Life / psychology
  • [MeSH-minor] Adult. Aged. Disease Progression. Dominance, Cerebral / physiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Complications / mortality. Postoperative Complications / psychology. Prognosis. Statistics as Topic. Survival Analysis

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1990 Jul 1;66(1):6-14 [2354409.001]
  • [Cites] Biol Psychiatry. 2003 Aug 1;54(3):269-82 [12893103.001]
  • [Cites] J Clin Oncol. 1996 Jan;14 (1):171-5 [8558193.001]
  • [Cites] Brain Res Brain Res Rev. 2003 May;42(2):97-122 [12738053.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1999 Apr;60(4):217-34 [10397403.001]
  • [Cites] J Am Geriatr Soc. 2000 Dec;48(12):1707-13 [11129765.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Mar;72(3):373-7 [11861699.001]
  • [Cites] Am J Psychiatry. 2000 May;157(5):683-94 [10784457.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):283-91 [16163448.001]
  • [Cites] Ann Med. 2001 Jul;33(5):328-36 [11491191.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2005 Apr;76(4):562-8 [15774446.001]
  • [Cites] J Neurosurg. 1989 Dec;71(6):826-36 [2585073.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):201-17 [15694227.001]
  • [Cites] Acta Neurol Scand. 1990 Jun;81(6):541-9 [2220313.001]
  • [Cites] Neurosurgery. 2004 Feb;54(2):358-66; discussion 366-7 [14744282.001]
  • [Cites] J Neurosurg. 1998 May;88(5):831-9 [9576250.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3381-8 [15310784.001]
  • [Cites] Lancet. 1989 Oct 14;2(8668):888-91 [2571815.001]
  • [Cites] J Clin Oncol. 1990 Feb;8(2):356-64 [2299375.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):495-504; discussion 495-504 [16145528.001]
  • [Cites] Biol Psychiatry. 2003 Aug 1;54(3):177-80 [12893090.001]
  • [Cites] Pancreas. 2006 Jan;32(1):58-61 [16340745.001]
  • [Cites] Neurosurgery. 2005 Jun;56(6):1234-41; discussion 1241-2 [15918939.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):1-10 [9420066.001]
  • [Cites] Lancet Oncol. 2004 Oct;5(10):617-25 [15465465.001]
  • [Cites] Strahlenther Onkol. 2003 Jan;179(1):8-15 [12540979.001]
  • [Cites] Med Hypotheses. 1998 Oct;51(4):309-14 [9824837.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1358-63 [16470608.001]
  • [Cites] Eur J Cancer. 2001 Oct;37(15):1895-903 [11576846.001]
  • [Cites] Eur J Cancer. 2005 Aug;41(12):1710-4 [16098457.001]
  • (PMID = 16960653.001).
  • [ISSN] 0940-1334
  • [Journal-full-title] European archives of psychiatry and clinical neuroscience
  • [ISO-abbreviation] Eur Arch Psychiatry Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


60. Yao Y, Tang X, Li S, Mao Y, Zhou L: Brain tumor stem cells: view from cell proliferation. Surg Neurol; 2009 Mar;71(3):274-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor stem cells: view from cell proliferation.
  • A small population of TSCs, which form neurospheres and possess the capacity for self-renewal, has been recently identified in adult and pediatric brain tumors.
  • They differentiate into phenotypically diverse populations, including neuronal, astrocytic, and oligodendroglial cells in vitro and recapitulate original tumors in vivo.
  • The understanding of brain TSCs has been greatly advanced by the knowledge of cell proliferation, which contributes to initiate and sustain the malignant phenotype.
  • In this article, the authors summarized the evidence of the presence of TSCs in human brain tumors and emphasized the significance of the proliferative status of TSCs.
  • Finally, the preliminary evidence that TSCs in malignant brain tumors have more proliferative capacity than stem/progenitor cells in benign brain tumors was discussed.
  • [MeSH-major] Adult Stem Cells / pathology. Brain Neoplasms / pathology. Neoplastic Stem Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249579.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


61. Qian ZY, Wu YY, Huang Q, Zhai DZ, Zhu Q, Wang AD, Huo HM, Lan Q: [Expression of SV40Tag, Rb and IRS-1 in glioma detected by tissue microarray and their relation with tumorigenesis and progression of gliomas]. Zhonghua Zhong Liu Za Zhi; 2008 Jun;30(6):432-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tissue microarrays were constructed containing 118 samples including human glioma and meningioma, experimental glioma, and normal human brain tissue.
  • RESULTS: The expressions of SV40Tag, Rb and IRS-1 were detected in gliomas and benign brain tumors.
  • Their positive expression rate in glioma was 65.9%, 64.6% and 48.8%, respectively, with a statistically non-significant difference between the malignant and benign brain tumors.
  • In the normal human brain tissue only the expression of Rb (77.8%, 7/9) and IRS-1 (22.2%, 2/9) were detected, but expression of SV40Tag could not be observed.
  • CONCLUSION: Our findings that no expression of SV40Tag was observed in normal human brain tissue indicates that expression of SV40Tag may play an important role in the pathogenesis of glioma.
  • [MeSH-major] Antigens, Polyomavirus Transforming / metabolism. Brain Neoplasms / metabolism. Glioma / metabolism. Insulin Receptor Substrate Proteins / metabolism. Retinoblastoma Protein / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Brain / metabolism. Brain / pathology. Cell Line, Tumor. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Meningioma / metabolism. Meningioma / pathology. Mice. Middle Aged. Neoplasm Transplantation. Rats. Rats, Sprague-Dawley. Tissue Array Analysis. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19024517.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / IRS1 protein, human; 0 / Insulin Receptor Substrate Proteins; 0 / Retinoblastoma Protein
  •  go-up   go-down


62. Tonsgard JH: Clinical manifestations and management of neurofibromatosis type 1. Semin Pediatr Neurol; 2006 Mar;13(1):2-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with variable expression.
  • Neurologic complications include tumors of the peripheral nerves, nerve roots, and plexi; spinal cord compression; dural ectasias; learning disabilities; attention deficit; headaches; seizures; brain tumors; deafness; hydrocephalus; and stroke.
  • High-intensity signals on brain magnetic resonance imaging are a frequent finding without known clinical significance.
  • Most brain tumors are benign and asymptomatic, but malignant brain tumors occur.
  • The major cause of death is malignancy, including brain tumors and malignant peripheral nerve sheath tumors.
  • [MeSH-major] Nervous System Neoplasms / complications. Nervous System Neoplasms / therapy. Neurofibromatosis 1 / complications. Neurofibromatosis 1 / therapy


63. Lim SD, Stallcup W, Lefkove B, Govindarajan B, Au KS, Northrup H, Lang D, Fisher DE, Patel A, Amin MB, Arbiser JL: Expression of the neural stem cell markers NG2 and L1 in human angiomyolipoma: are angiomyolipomas neoplasms of stem cells? Mol Med; 2007 Mar-Apr;13(3-4):160-5
Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the neural stem cell markers NG2 and L1 in human angiomyolipoma: are angiomyolipomas neoplasms of stem cells?
  • Angiomyolipomas are benign tumors of the kidney which express phenotypes of smooth muscle, fat, and melanocytes.
  • These tumors appear with increased frequency in the autosomal dominant disorder tuberous sclerosis and are the leading cause of morbidity in adults with tuberous sclerosis.
  • While benign, these tumors are capable of provoking life threatening hemorrhage and replacement of the kidney parenchyma, resulting in renal failure.
  • The histogenesis of these tumors is currently unclear, although currently, we believe these tumors arise from "perivascular epithelioid cells" of which no normal counterpart has been convincingly demonstrated.
  • Immunohistochemistry of human angiomyolipoma specimens revealed uniform staining of tumor cells, while renal cell carcinomas revealed positivity only of angiogenic vessels.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 1982 Dec 1;156(6):1755-66 [7175440.001]
  • [Cites] Dev Biol. 1981 Apr 15;83(1):154-65 [7016634.001]
  • [Cites] Mayo Clin Proc. 1991 Aug;66(8):792-6 [1861550.001]
  • [Cites] Neuron. 1991 Aug;7(2):209-20 [1873027.001]
  • [Cites] Science. 1991 Oct 25;254(5031):571-3 [1658930.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Aug 21;68(2):193-201 [1394967.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1305-15 [8269512.001]
  • [Cites] Genes Dev. 1994 Aug 15;8(16):1875-87 [7958863.001]
  • [Cites] Genes Dev. 1994 Aug 15;8(16):1888-96 [7958864.001]
  • [Cites] Hum Mol Genet. 1994;3 Spec No:1477-80 [7849741.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11279-83 [7479979.001]
  • [Cites] Am J Hum Genet. 1996 Aug;59(2):400-6 [8755927.001]
  • [Cites] J Neurosci Res. 1996 Feb 1;43(3):299-314 [8714519.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15294-8 [8986805.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1639-47 [9403714.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):21-40 [9503504.001]
  • [Cites] Am J Hum Genet. 1998 Apr;62(4):810-5 [9529362.001]
  • [Cites] Cancer Res. 1998 Nov 1;58(21):4766-70 [9809973.001]
  • [Cites] J Cell Sci. 1999 Mar;112 ( Pt 6):905-15 [10036240.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):295-9 [10088548.001]
  • [Cites] Development. 1999 Jun;126(11):2495-503 [10226008.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2869-74 [10383148.001]
  • [Cites] Nature. 2005 Jul 7;436(7047):117-22 [16001072.001]
  • [Cites] J Biol Chem. 2006 Aug 4;281(31):21582-7 [16737956.001]
  • [Cites] J Cell Sci. 1999 Dec;112 ( Pt 24):4739-49 [10574721.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):28625-33 [10889192.001]
  • [Cites] J Clin Invest. 2000 Oct;106(8):963-71 [11032856.001]
  • [Cites] Oncogene. 2001 Jan 4;20(1):48-57 [11244503.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):483-91 [11485907.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1541-54 [11583980.001]
  • [Cites] Dev Dyn. 2001 Oct;222(2):218-27 [11668599.001]
  • [Cites] FASEB J. 2002 Apr;16(6):586-8 [11919162.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):781-6 [12213705.001]
  • [Cites] Neurobiol Dis. 2003 Nov;14(2):279-90 [14572449.001]
  • [Cites] J Urol. 1986 Jun;135(6):1121-4 [3520013.001]
  • (PMID = 17592550.001).
  • [ISSN] 1076-1551
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / P30 AR 42687; United States / NIAMS NIH HHS / AR / R01 AR050727; United States / NIAMS NIH HHS / AR / P30 AR042687; United States / NIAMS NIH HHS / AR / R01AR 47901; United States / NIAMS NIH HHS / AR / R01 AR 050727; United States / NIAMS NIH HHS / AR / R01 AR047901
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Biomarkers, Tumor; 0 / Leukocyte L1 Antigen Complex; 0 / Proteoglycans; 0 / chondroitin sulfate proteoglycan 4
  • [Other-IDs] NLM/ PMC1892760
  •  go-up   go-down


64. Floricel F, Higaki K, Maki H, Nanba E, Ninomiya H, Ohno K: Antisense suppression of TSC1 gene product, hamartin, enhances neurite outgrowth in NGF-treated PC12h cells. Brain Dev; 2007 Sep;29(8):502-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberous sclerosis complex (TSC) is an autosomal dominant inherited disorder characterized by benign tumors (hamartomas) in various organs.
  • The brain is one of the most severely affected organs with neuropsychiatric disorders including epilepsy, mental retardation and autism.
  • [MeSH-major] DNA, Antisense. Nerve Growth Factor / metabolism. Neurites / metabolism. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Animals. Blotting, Western. Cell Differentiation. Cell Line, Tumor. Fluorescent Antibody Technique. Gene Expression. Neurons / cytology. Neurons / metabolism. Rats. Transfection. Tuberous Sclerosis / genetics. Tuberous Sclerosis / physiopathology. rhoA GTP-Binding Protein / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17376623.001).
  • [ISSN] 0387-7604
  • [Journal-full-title] Brain & development
  • [ISO-abbreviation] Brain Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Antisense; 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein; 9061-61-4 / Nerve Growth Factor; EC 3.6.5.2 / rhoA GTP-Binding Protein
  •  go-up   go-down


65. Scoles DR: The merlin interacting proteins reveal multiple targets for NF2 therapy. Biochim Biophys Acta; 2008 Jan;1785(1):32-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The neurofibromatosis 2 (NF2) tumor suppressor protein merlin is commonly mutated in human benign brain tumors.
  • Review of all of the merlin interacting proteins and functional consequences of losses of these interactions reveals multiple merlin actions in PI3-kinase, MAP kinase and small GTPase signaling pathways that might be targeted to inhibit the proliferation of NF2 tumors.
  • [MeSH-minor] Animals. Binding Sites. Cytoskeletal Proteins / metabolism. Humans. Models, Biological. Protein Folding. Tumor Suppressor Proteins / administration & dosage. Tumor Suppressor Proteins / metabolism

  • FlyBase. FlyBase .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980164.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 0 / Neurofibromin 2; 0 / Tumor Suppressor Proteins; 0 / ezrin
  • [Number-of-references] 210
  •  go-up   go-down


66. Dua RK, Devi BI, Yasha TC: Increased expression of Aquaporin-4 and its correlation with contrast enhancement and perilesional edema in brain tumors. Br J Neurosurg; 2010 Aug;24(4):454-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of Aquaporin-4 and its correlation with contrast enhancement and perilesional edema in brain tumors.
  • INTRODUCTION: Aquaporins and astrocytes are important in maintaining water hemostasis in brain.
  • Upregulation of AQP-4 has been described in conditions associated with brain edema.
  • AIMS: To study the expression of aquaporin-4 in brain tumors and its correlation with contrast enhancement and perilesional edema.
  • MATERIAL AND METHODS: 30 cases of brain tumors, both benign and malignant were included in the study to look for expression of AQP-4.
  • RESULTS: AQP-4 expression was increased in brain tumors compared to normal brain but distribution and intensity of expression depend upon the type of tumor.
  • CONCLUSION: AQP-4 expression was seen in tumor tissue and perilesional reactive astrocytes in primary brain tumors, however only perilesional astrocytes showed positivity in secondary brain tumors.
  • AQP-4 could be playing a role in alteration of blood-brain barrier leading to contrast enhancement and perilesional edema.
  • Increased knowledge of Aquaporins may open new targeted therapy for brain edema.
  • [MeSH-major] Aquaporin 4 / metabolism. Astrocytes / metabolism. Brain Edema / metabolism. Brain Neoplasms / metabolism. Contrast Media / metabolism
  • [MeSH-minor] Blood-Brain Barrier / metabolism. Female. Humans. Male. Up-Regulation

  • Genetic Alliance. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20536289.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aquaporin 4; 0 / Contrast Media
  •  go-up   go-down


67. Stewart DR, Sloan JL, Yao L, Mannes AJ, Moshyedi A, Lee CC, Sciot R, De Smet L, Mautner VF, Legius E: Diagnosis, management, and complications of glomus tumours of the digits in neurofibromatosis type 1. J Med Genet; 2010 Aug;47(8):525-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis, management, and complications of glomus tumours of the digits in neurofibromatosis type 1.
  • BACKGROUND: Glomus tumours are benign painful tumours of the glomus body, a thermoregulatory shunt in the digits.
  • Glomus tumours of the fingers and toes are associated with the monogenic disorder neurofibromatosis type 1 (NF1) and are recently recognised as part of the NF1 phenotype.
  • There is often a delay in diagnosis of many years and clinical suspicion is key to diagnosis, although magnetic resonance imaging may be useful in some scenarios.
  • Surgical extirpation can be curative; however, local tumour recurrence and metachronous tumours are common.
  • [MeSH-major] Fingers / pathology. Glomus Tumor / complications. Glomus Tumor / diagnosis. Neurofibromatosis 1 / complications. Toes / pathology

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Orthop Belg. 2000 Apr;66(2):169-73 [10842878.001]
  • [Cites] J Dermatol. 2000 Jun;27(6):418-9 [10920593.001]
  • [Cites] J Hand Surg Br. 2002 Jun;27(3):229-31 [12074607.001]
  • [Cites] J Med Genet. 2002 Aug;39(8):e45 [12161612.001]
  • [Cites] N Engl J Med. 2002 Sep 12;347(11):854-5; author reply 854-5 [12226162.001]
  • [Cites] Hand Clin. 2002 Nov;18(4):655-70; discussion 671 [12516980.001]
  • [Cites] Brain. 2004 Sep;127(Pt 9):1993-2009 [15289270.001]
  • [Cites] Plast Reconstr Surg. 2004 Nov;114(6):1486-9 [15509936.001]
  • [Cites] J Am Acad Dermatol. 1995 Feb;32(2 Pt 1):277-8 [7829715.001]
  • [Cites] Radiology. 1995 May;195(2):507-15 [7724775.001]
  • [Cites] J Hand Surg Br. 1996 Apr;21(2):257-60 [8732413.001]
  • [Cites] Int Angiol. 1995 Sep;14(3):226-8 [8919238.001]
  • [Cites] Int J Dermatol. 1997 Dec;36(12):894-900 [9466193.001]
  • [Cites] Brain. 1999 Mar;122 ( Pt 3):473-81 [10094256.001]
  • [Cites] J Dermatol. 1999 Aug;26(8):535-7 [10487011.001]
  • [Cites] J Med Genet. 2004 Nov;41(11):837-41 [15520408.001]
  • [Cites] J Hand Surg Br. 2005 Oct;30(5):535-40 [16085343.001]
  • [Cites] J Hand Surg Am. 2006 Oct;31(8):1397-400 [17027805.001]
  • [Cites] J Med Genet. 2007 Feb;44(2):81-8 [17105749.001]
  • [Cites] Arch Pathol Lab Med. 2008 Sep;132(9):1448-52 [18788860.001]
  • [Cites] Sheng Li Xue Bao. 2008 Oct 25;60(5):581-3 [18958364.001]
  • [Cites] Clin Med. 2008 Dec;8(6):611-7 [19149284.001]
  • [Cites] Pain Pract. 2009 Mar-Apr;9(2):86-99 [19215592.001]
  • [Cites] Cancer Res. 2009 Sep 15;69(18):7393-401 [19738042.001]
  • (PMID = 20530151.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA CP010144-13
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS387951; NLM/ PMC3412429
  •  go-up   go-down


68. Zhou J, Li NY, Zhou XJ, Zhou HB, Wu B, Jiang SJ, Ma HH, Zhang RS: [Clinicopathologic study of von Hippel-Lindau syndrome-related and sporadic hemangioblastomas of central nervous system]. Zhonghua Bing Li Xue Za Zhi; 2010 Mar;39(3):145-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study clinicopathologic features, diagnosis, treatment and prognosis of von Hippel-Lindau (VHL) syndrome-related and sporadic hemangioblastomas of the central nervous system (CNS-HB).
  • There were 10 patients presenting other lesions related to VHL, including 6 retinal HBs, 4 pancreatic tumors (endocrine tumor and microcystic cystadenoma), 1 clear renal cell carcinoma, 4 renal cysts and 1 endolymphatic sac tumor.
  • One patient developed 5 different tumors related to VHL within a period of 4 years.
  • Histologically, the tumors showed large and vacuolated stromal cells.
  • Some tumors showed atypical nuclei.
  • Involvement of the brain tissue was seen in 32 cases, among which, 21 patients with available follow-up information were learnt to be alive.
  • Tumor cells of HB stained positive for vimentin, EGFR, Inhibin alpha and D2-40, but negative for CD34 and CD68.
  • CONCLUSIONS: VHL syndrome is a multisystem disorder with a poor prognosis and a high rate of missed diagnosis.
  • The syndrome is characterized by development of various benign and malignant tumors.
  • The most common tumor is CNS-HB, which occurs predominantly in the cerebellum.
  • Patients with VHL syndrome tend to present at a younger age than patients with sporadic CNS-HBs, and VHL related HB occurs more predominantly in the brain stem and spinal cord.
  • Prognosis of CNS-HB patients is not correlated with the nuclear atypicality, expression for Ki-67 and involvement of the brain tissue.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Hemangioblastoma / pathology. von Hippel-Lindau Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Child. Female. Follow-Up Studies. Glial Fibrillary Acidic Protein / metabolism. Humans. Inhibins / metabolism. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Receptor, Epidermal Growth Factor / metabolism. Retinal Neoplasms / metabolism. Retinal Neoplasms / pathology. Retinal Neoplasms / surgery. Survival Analysis. Vimentin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Von Hippel-Lindau syndrome.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450758.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Vimentin; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


69. Chen H, Sun XF, Wu JS: [Clinicopathologic study of subependymal giant cell astrocytoma]. Zhonghua Bing Li Xue Za Zhi; 2006 Nov;35(11):656-9
Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor often occurred in the lateral ventricles (16/18, 88.9%).
  • CONCLUSIONS: Subependymal giant cell astrocytoma is a benign brain tumor with distinctive histopathologic features.
  • The tumor typically affects children and young adults.
  • [MeSH-major] Astrocytoma / pathology. Cerebral Ventricle Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374208.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Synaptophysin
  •  go-up   go-down


70. Aihara N, Mase M, Yamada K: [Treatment of benign brain tumor in elderly patients]. Nihon Rinsho; 2005 Sep;63 Suppl 9:600-6
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of benign brain tumor in elderly patients].
  • [MeSH-major] Adenoma / therapy. Cochlear Nerve / surgery. Cranial Nerve Neoplasms / therapy. Pituitary Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16201588.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Dopamine Agonists; 3A64E3G5ZO / Bromocriptine
  • [Number-of-references] 13
  •  go-up   go-down


71. McDonald A: Living with a benign brain tumour. BMJ; 2009;339:b2886
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Living with a benign brain tumour.
  • [MeSH-major] Brain Neoplasms / psychology. Glioma, Subependymal / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19638372.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


72. Fukuoka S: [Stereotactic irradiation (Gamma knife) for benign brain tumors]. Nihon Rinsho; 2005 Sep;63 Suppl 9:412-8
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Stereotactic irradiation (Gamma knife) for benign brain tumors].
  • [MeSH-major] Cochlear Nerve. Cranial Nerve Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Pituitary Neoplasms / surgery. Radiosurgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16201556.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 9
  •  go-up   go-down


73. Meningioma. Understanding this usually benign brain tumor. Mayo Clin Health Lett; 2010 Jul;28(7):4-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma. Understanding this usually benign brain tumor.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Health Knowledge, Attitudes, Practice. Meningioma / diagnosis. Meningioma / therapy

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20799379.001).
  • [ISSN] 0741-6245
  • [Journal-full-title] Mayo Clinic health letter (English ed.)
  • [ISO-abbreviation] Mayo Clin Health Lett
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement